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A B S T R A C T
Background
Surgery is an important part of the management of oral cavity cancer with regard to both the removal of the primary tumour and
removal of lymph nodes in the neck. Surgery is less frequently used in oropharyngeal cancer. Surgery alone may be treatment for
early-stage disease or surgery may be used in combination with radiotherapy, chemotherapy and immunotherapy/biotherapy. There is
variation in the recommended timing and extent of surgery in the overall treatment regimens of people with these cancers. This is an
update of a review originally published in 2007 and first updated in 2011.
Objectives
To determine which surgical treatment modalities for oral and oropharyngeal cancers result in increased overall survival, disease-free
survival and locoregional control and reduced recurrence. To determine the implication of treatment modalities in terms of morbidity,
quality of life, costs, hospital days of treatment, complications and harms.
Search methods
CochraneOralHealth’s Information Specialist searched the following databases: CochraneOralHealth’s Trials Register (to 20December
2017), theCochraneCentral Register of ControlledTrials (CENTRAL; 2017, Issue 11),MEDLINEOvid (1946 to 20December 2017)
and Embase Ovid (1980 to 20 December 2017). We searched the US National Institutes of Health Trials Registry (ClinicalTrials.gov)
and the World Health Organization International Clinical Trials Registry Platform for ongoing trials. There were no restrictions on
the language or date of publication.
Selection criteria
Randomised controlled trials where more than 50% of participants had primary tumours of the oral cavity or oropharynx, or where
separate data could be extracted for these participants, and that compared two or more surgical treatment modalities, or surgery versus
other treatment modalities.
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Data collection and analysis
Twoormore review authors independently extracted data and assessed risk of bias.We contacted study authors for additional information
as required. We collected adverse events data from included studies.
Main results
We identified five new trials in this update, bringing the total number of included trials to 12 (2300 participants; 2148 with cancers of
the oral cavity). We assessed four trials at high risk of bias, and eight at unclear. None of the included trials compared different surgical
approaches for the excision of the primary tumour. We grouped the trials into seven main comparisons.
Future research may change the findings as there is only very low-certainty evidence available for all results.
Five trials compared elective neck dissection (ND) with therapeutic (delayed) ND in participants with oral cavity cancer and clinically
negative neck nodes, but differences in type of surgery and duration of follow-up made meta-analysis inappropriate in most cases.
Four of these trials reported overall and disease-free survival. The meta-analyses of two trials found no evidence of either intervention
leading to greater overall survival (hazard ratio (HR) 0.84, 95% confidence interval (CI) 0.41 to 1.72; 571 participants), or disease-free
survival (HR 0.73, 95% CI 0.25 to 2.11; 571 participants), but one trial found a benefit for elective supraomohyoid ND compared to
therapeutic ND in overall survival (RR 0.40, 95% CI 0.19 to 0.84; 67 participants) and disease-free survival (HR 0.32, 95% CI 0.12
to 0.84; 67 participants). Four individual trials assessed locoregional recurrence, but could not be meta-analysed; one trial favoured
elective ND over therapeutic delayed ND, while the others were inconclusive.
Two trials compared elective radical ND with elective selective ND, but we were unable to pool the data for two outcomes. Neither
study found evidence of a difference in overall survival or disease-free survival. A single trial found no evidence of a difference in
recurrence.
One trial compared surgery plus radiotherapy with radiotherapy alone, but data were unreliable because the trial stopped early and
there were multiple protocol violations.
One trial comparing positron-emission tomography-computed tomography (PET-CT) following chemoradiotherapy (with ND only
if no or incomplete response) versus planned ND (either before or after chemoradiotherapy), showed no evidence of a difference in
mortality (HR 0.92, 95% CI 0.65 to 1.31; 564 participants). The trial did not provide usable data for the other outcomes.
Three single trials compared: surgery plus adjunctive radiotherapy versus chemoradiotherapy; supraomohyoid ND versus modified
radical ND; and super selective ND versus selective ND. There were no useable data from these trials.
The reporting of adverse events was poor. Four trials measured adverse events. Only one of the trials reported quality of life as an
outcome.
Authors’ conclusions
Twelve randomised controlled trials evaluated ND surgery in people with oral cavity cancers; however, the evidence available for
all comparisons and outcomes is very low certainty, therefore we cannot rely on the findings. The evidence is insufficient to draw
conclusions about elective ND of clinically negative neck nodes at the time of removal of the primary tumour compared to therapeutic
(delayed) ND. Two trials combined in meta-analysis suggested there is no difference between these interventions, while one trial (which
evaluated elective supraomohyoid ND) found that it may be associated with increased overall and disease-free survival. One trial found
elective ND reduced locoregional recurrence, while three were inconclusive. There is no evidence that radical ND increases overall or
disease-free survival compared to more conservative ND surgery, or that there is a difference in mortality between PET-CT surveillance
following chemoradiotherapy versus planned ND (before or after chemoradiotherapy). Reporting of adverse events in all trials was poor
and it was not possible to compare the quality of life of people undergoing different surgical treatments.
P L A I N L A N G U A G E S U M M A R Y
Surgical treatments for oral cavity (mouth) and oropharyngeal (throat) cancers
Review question
We evaluated clinical trials of surgical treatments for oral and oropharyngeal cancers to find out which were most likely to result in
people with these cancers living longer (overall survival). living longer without symptoms (disease-free survival), and not experiencing
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a recurrence of the cancer at the same site or spread to other sites. We also wanted to find out how different treatments affect disease
symptoms, quality of life, time in hospital, complications, side effects and cost.
Background
Oral cancer is among the most common cancers worldwide, with more than 400,000 new cases diagnosed in 2012. The treatment
of these cancers can involve surgery, chemotherapy, radiotherapy, or a combination of two or all three therapies. This topic area was
identified as a priority by an expert working group for oral and maxillofacial surgery in 2014. Authors working with Cochrane Oral
Health conducted this review, which is an update of a review originally published in 2007 and first updated in 2011. The evidence is
current to 20 December 2017.
Study characteristics
We included 12 trials (five new for this update) that investigated the success of surgical treatment for oral cancers. The studies involved
2300 participants, 2148 of whom had mouth cancers. The trials included seven comparisons of different treatment options. None of
them compared different surgical approaches for cutting out the primary tumour.
Key results
The findings of the studies are mixed and it is not possible to draw firm conclusions about the optimal surgical approach for mouth
and throat cancers.
Surgical removal of the lymph nodes in the neck that appear to be cancer-free, at the same time as the cancer is removed did not seem
to be associated with longer survival in two studies whose results were combined. Another study, however, suggested there may be a
benefit of early neck surgery in terms of overall survival and ’disease-free survival’ (length of time after primary treatment without signs
and symptoms of disease). One study found cancer recurrence at or around the same site was less likely with the early surgery, while
three other studies did not favour either treatment.
There was no evidence that removal of all the lymph nodes in the neck resulted in longer survival compared to selective surgical removal
of affected lymph nodes.
One study evaluated use of a special scan (positron-emission tomography-computed tomography (PET-CT)), after a combination of
chemotherapy and radiotherapy, to guide decisions about neck dissection, and found no difference in mortality (death) compared with
undertaking a planned neck dissection before or after chemoradiotherapy.
There were a number of other surgical approaches compared in the studies, but we were unable to use the results in this review.
Although removal of lymph nodes from the neck is known to be associated with significant negative effects related to appearance and
functions such as eating, drinking and speaking, the studies reported poorly on these side effects and did not measure quality of life
accurately enough or in large enough numbers to be included in any of our analyses.
Certainty of the evidence
The certainty of the evidence was very low as there were few studies for each comparison and they were at risk of bias because of the
way they were designed. Some comparisons and outcomes had no useable results.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Elective neck dissection versus therapeutic (delayed) neck dissection
Patient: adults with oral or oropharyngeal cancer
Setting: inpat ient
Intervention: elect ive neck dissect ion
Comparison: therapeut ic (delayed) neck dissect ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Assumed risk Corresponding risk
Therapeutic neck dis-
section
Elective neck dissec-
tion
Total mortality
(follow-up: 3 years)
500a per 1000 441 per 1000 (247 to
696)
HR 0.84
(0.41 to 1.72)
571
(2)
⊕©©©
Very lowb,c,d
These data were f rom
the HR for overall sur-
vival.
Other binary data f rom
2 trials could not be
pooled. 1 trial indicated
no clear evidence of ei-
ther intervent ion lead-
ing to lower mortality;
however, 1 small t rial
indicated elect ive neck
dissect ion led to lower
mortality (RR 0.40, 95%
CI 0.19 to 0.84) (very
low-certainty evidence)
New disease, progres-
sion or mortality
(follow-up: 3 years)
500e per 1000 397.1 per 1000 (159 to
768)
HR 0.73
(0.25 to 2.11)
571
(2)
⊕©©©
Very lowb,c
These data were f rom
the HR for disease-f ree
survival.
Binary data f rom 2 tri-
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als did not favour either
intervent ion. 1 trial pro-
vided some very low-
certainty evidence for
elect ive SOH leading to
lower mortality (HR 0.
32, 95%CI 0.12 to 0.84)
250e per 1000 190 per 1000 (69 to
455)
Locoregional recur-
rence
- - - 278
(4)
⊕©©©
Very lowc,f
Binary data; unable to
pool data (dif f erent t im-
ings). Three studies
were inconclusive and
one favoured elect ive
procedure
Recurrence - - - 0
(0)
- No data presented
Adverse events 1 study showed that 6.6% of elect ive-surgery part icipants reported adverse events, while 3.6% of part icipants in therapeut ic-surgery group reported
adverse events. These adverse events included: neck haematoma, chyle leak, oral bleeding, postoperat ive infect ion and anaphylaxis. None of the
other trials reported on adverse events
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; HR: hazard rat io; RR: risk rat io; SOH: supraomohyoid neck dissect ion.
GRADE Working Group grades of evidence
High certainty: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate certainty: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low certainty: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low certainty: we are very uncertain about the est imate.
aBased on data presented by Warnakulasuriya 2009.
bDowngraded once as two trials at unclear risk of bias.
cDowngraded twice for imprecision.
dDowngraded once for heterogeneity.
ePurely illustrat ive, unable to f ind any epidemiological est imates.
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fDowngraded once for study design; four heterogeneous trials, two at high risk of bias and two at unclear risk of bias.
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B A C K G R O U N D
Description of the condition
Head and neck cancers (HNC) comprise laryngeal, pharyngeal
andoral cancers. Collectively, they are the sixthmost commoncan-
cer in the world, accounting for approximately 5%of all malignant
tumours (Torre 2015). HNC generally have common risk factors
and aetiology (Winn 2015); however, since the late 2000s, oropha-
ryngeal (throat) cancers have increasingly been associated with hu-
man papillomavirus (HPV), unlike other oral cancers (D’Souza
2007). The tumours do not always recognise the boundaries be-
tween the oral cavity and oropharynx, with tumours frequently
overlapping these sites (Tapia 2011).
HNCs are increasingly treated by multidisciplinary HNC teams
in centralised units (Hughes 2012; Lo Nigro 2017). Clinical trials
have generally recruited people with HNCs as if this was a single
disease entity (Adelstein 2009). This influences the evidence base
available to draw from in a systematic review.
Oral cancer (defined here to include both oral cavity and orophar-
ynx cancers) is among the most common cancers worldwide, with
approximately 442,760 incident cases and 241,418 deaths re-
ported in 2012 (Ferlay 2013; Stewart 2014). There are geographi-
cal variations in the incidence of oral cancers, with increase among
men and women in some European countries, stabilisation in cer-
tainAsian countries, anddecrease inCanada andUSA (Chaturvedi
2013; Simard 2014). In the UK, incidence trends are continuing
to rise, driven mainly by oropharyngeal cancer rates (Louie 2015;
Purkayastha 2016). Survival following a diagnosis of oral cavity or
oropharyngeal cancer remains poor with five-year survival around
50% overall, with only limited improvement since the late 1980s
(Warnakulasuriya 2009).
There is overwhelming evidence that tobacco use, alcohol con-
sumption and betel quid chewing are the main risk factors in the
aetiology of oral cancer (Gupta 2014; LaVecchia 1997;Macfarlane
1995; Winn 2015). There is also strong evidence that low socioe-
conomic status (educational attainment and income) is associated
with substantial increased risk not explained by tobacco and alco-
hol (Conway 2015). There is a higher incidence of oral cancers
among men (Freedman 2007), and the vast majority of cases occur
in men over 50 years of age (Warnakulasuriya 2009), and among
low socioeconomic groups (Conway 2008). However, the ratio of
males to females diagnosed with oral cancers has changed from
approximately 5:1 in the 1960s to less than 2:1 after 2000 (Parkin
2005; Purkayastha 2016).
Two distinct types of oropharyngeal cancer exist as classified ac-
cording toHPV status.HPV-negative oropharyngeal cancer is epi-
demiologically similar to the traditional type of cancer of the upper
aerodigestive tract, in which long-term exposure to tobacco and
alcohol products leads to development of malignancy. HPV-pos-
itive oropharyngeal cancer starts with exposure to high-risk HPV,
most often HPV 16, and can develop independently of tobacco
or alcohol exposure (Gillison 2000). People with HPV-positive
oropharyngeal cancer are more likely to be male and of a relatively
younger age than their HPV-negative counterparts (Chaturvedi
2008; Chaturvedi 2015; Gillison 2007). Moreover, they have a
better overall performance and are less likely to be smokers or
heavy alcohol consumers (Gillison 2000). In theUS, it is suggested
that more the 70% of oropharyngeal cancers are HPV positive
(Chaturvedi 2011).
The link between oncogenic HPV and oropharyngeal cancer is
strong and has been documented in numerous studies, fulfilling
the epidemiological criteria for disease causality, especially in the
development of oropharyngeal cancer in non-smokers (Sturgis
2007). Since the early 1990s, the proportion of people with
oropharyngeal cancer who areHPV positive has increased dramat-
ically (Attner 2010; Ryerson 2008), but it is interesting to note
that this group of people have significantly improved rates of both
overall survival and disease-free survival (Adelstein 2009; Fakhry
2006; Fakhry 2008; Licitra 2006), and more recent trials are be-
ginning to treat HPV-positive oropharyngeal cancers differently
(Blanchard 2011; Holsinger 2015; Parsons 2002). There is evi-
dence to suggest that the rate of oral cavity cancer has reached a
plateau, whereas the proportion of people developing oropharyn-
geal cancer is increasing and is projected to continue to increase
(Purkayastha 2016).
Description of the intervention
Surgery can be combined with one or more other treatments, that
is, radiotherapy, chemotherapy and immunotherapy/biotherapy;
the sequence of these combination therapies is considered impor-
tant. Radiotherapy is typically now administered postoperatively.
Chemotherapy can be given: 1. before surgery (induction/neoad-
juvant - when treatment is administered before the primary ther-
apy, e.g. to shrink a tumour prior to surgery or radiation); 2. after
surgery (adjuvant - administered after the primary therapy, e.g.
when the primary therapy to treat a cancerous tumour is surgery,
chemotherapy would be considered an adjuvant therapy) and be-
fore radiotherapy; 3. at the same time as radiotherapy (concomi-
tant/concurrent - it may also be referred to as chemoradiother-
apy); or 4. alternating with radiotherapy. In recent years, a form
of radiotherapy called intensity-modulated radiotherapy (IMRT)
has been used to treat oral cancers, which uses use higher radiation
doses than traditional therapies with a better chance of locore-
gional control while sparing more of the surrounding healthy oral
tissue from harmful doses and effects of radiation (Brennan 2017;
Studer 2007).
The locoregional control of the primary tumour is the main cri-
terion of successful treatment. Tumours are excised with a mar-
gin of clinically normal tissue (typically between 1 cm and 2
cm in the UK). Despite this apparent complete clinical surgi-
cal excision, the tumour may still be demonstrated at the mar-
gins histopathologically; this has prognostic implications (Batsakis
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1999; Sutton 2003). Margins apparently histologically free of tu-
mour may demonstrate molecular changes and the presence of
such tumour clonogen populations at the margins may be predic-
tive for disease progression (Partridge 2000).
Spread of the tumour to the regional lymph nodes within the neck
(cervical nodes) is an early and consistent event in the natural
history of oral and oropharyngeal cancers (Haddadin 2000). The
extent of cervical involvement is reflected in the staging of the
tumour and has prognostic implications (Shah 1990). Therefore,
surgical dissection of the cervical lymph nodes at risk of metasta-
sis may be undertaken as part of the management of the primary
tumour. The classic radical neck dissections (RND) removed all
of the cervical lymph nodes from levels I to V combined with the
sternocleidomastoid muscle, internal jugular vein, submandibu-
lar gland and the spinal accessory nerve, with resultant significant
postoperativemorbidity particularly in relation to loss of the acces-
sory nerve. In one study of 100 cases following RND, almost half
of the participants experienced shoulder pain, shoulder droop and
a reduction in the range of motion (Ewing 1952). One more re-
cent study comparing RND with accessory nerve-sparing surgery
found all of the cases with RND had severe shoulder dysfunction
comparedwith only 7%of the caseswhohadnerve-sparing surgery
(Umeda 2010). RND is now only reserved for advanced neck dis-
ease. Modifications of the neck dissection to preserve some or all
of the associated structures have reduced morbidity and may now
be undertaken as selective neck dissections (Carew 2003; Robbins
2002). There has been an increasing trend of using selective neck
dissection as a therapeutic procedure in the clinically N0 neck (in-
dicating no palpable nodes on clinical examination). In addition
to the extent of neck disease at presentation, spread of the tumour
outside the capsule of the lymph nodes (extracapsular spread) is
also an indicator of a poor prognosis (Woolgar 2003). Distant
metastasis is uncommon inHNCwith one study reporting 13.8%
in 1022 cases (Duprez 2017). Locoregional disease recurrence re-
mains the dominant mode of treatment failure for people with
advanced tumours (Brizel 1998). Historically, clinicians treating
oral cancer did not focus on distant metastatic disease because
locoregional control had been the main cause of death and there
were fewer effective chemotherapeutic agents to deal with distant
metastases. With improvements in locoregional control, distant
metastases are an increasing issue in the management of oral can-
cer.
When early stage tumours (T1, less than 2 cm, or T2, 2 cm to 4
cm) present with apparently clinically negative neck nodes, there
is controversy over the management of the cervical lymph nodes
(Woolgar 2003). To date, imaging of the head and neck region is
not sensitive enough to identify nodal micrometastases as the rate
of occult metastases has been reported as 23% to 43% (Ebrahimi
2012). Studies have demonstrated an improved outcome when a
neck dissection has been undertaken at the same time as the re-
section of the primary tumour rather than waiting for neck dis-
ease to present subsequently (Haddadin 2000; Hughes 1993), al-
though others adopt a ’wait and ’ policy. One current clinical
guideline recommends that T1 and T2 oral cancer with a clinically
negative neck should receive prophylactic neck treatment (Paleri
2016). However, this implies overtreatment and treatment-associ-
ated morbidity in the majority of people (Dias 2001). There is ev-
idence of improved overall and disease-free survival in people with
early-stage oral squamous-cell cancer (SCC) who had an elective
neck dissection in comparison with therapeutic neck dissection
(D’Cruz 2015).
The use of sentinel node biopsy (SNB) is now being advocated for
small tumours with a clinically negative neck. One UK guideline
recommends that biopsy should be offered to people with oral can-
cer (T1-T2N0), as it is in the Netherlands and Denmark (Holden
2018; NICE 2018). One European study reported a sensitivity of
86% and negative predictive value of 95% with SNB and con-
cluded that this is a reliable and safe oncological technique for
staging the clinically N0 neck in people with T1 and T2 oral can-
cer (Schilling 2015). Yang 2017 also indicated that a high sensitiv-
ity and negative predictive value have been reported with SNB in
a larger study including meta-analysis of cT1/T2N0 people with
tongue SCC. The widespread introduction of SNB for oral SCC
will result in individual treatment that enables people at high risk
to be suitably treated early in the disease process, and people at
low risk to be spared unnecessary surgery (Schilling 2017).
Why it is important to do this review
Cochrane Oral Health undertook an extensive prioritisation exer-
cise in 2014 to identify a core portfolio of titles that were the most
clinically important ones to maintain on the Cochrane Library
(Worthington 2015). The Oral and Maxillofacial Surgery Expert
Panel identified this review as a priority (Cochrane Oral Health
Priority Reviews).
The management of advanced oral cavity and oropharyngeal can-
cers is problematic and has traditionally relied on surgery and ra-
diotherapy, both of which are associated with substantial adverse
effects. Although there have been new treatments developed, there
has been limited improvement in survival since the late 1970s
(Warnakulasuriya 2009). Oropharyngeal cancers have relatively
’silent’ symptoms, whichmay not be present during the early stages
of the disease. This is a possible explanation for the fact that the
disease stage at diagnosis has not altered since the 1960s despite
public education (McGurk 2005). Tumour recurrence and the
development of multiple primary tumours are the major causes
of treatment failure (Day 1992; Partridge 2000; Woolgar 2003).
Surgical treatment may be disfiguring and result in a substantially
reduced quality of life as people with oral and oropharyngeal can-
cers are socially isolated, due to difficulties with altered appear-
ance, speech, eating and drinking. Developments in the way in
which surgery is delivered aim to improve its efficacy and reduce
the impact on people’s quality of life.
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This review was undertaken as part of a series of reviews look-
ing at the different treatment modalities for oral cancer (Furness
2011; Glenny 2010): surgery, chemotherapy, radiotherapy and
immunotherapy. In this update of our surgical review, we aimed
to answer two broad questions.
• Does surgery, in addition to chemotherapy, radiotherapy or
chemoradiotherapy, improve outcomes for people with oral
cavity and oropharyngeal cancers?
• Which type of surgery improves outcomes for people with
oral cavity and oropharyngeal cancers?
In this surgical review, we included all randomised controlled tri-
als (RCTs) where more than 50% of participants had primary
tumours in the oral cavity or oropharynx or where separate data
could be extracted for these types of cancer. We included only
trials where participants in each treatment arm received different
surgical interventions (either different techniques or timing); or
radiotherapy, chemotherapy or chemoradiotherapy with or with-
out surgery; or surgery versus no surgery.
O B J E C T I V E S
Primary objective
To determine which surgical treatment modalities for oral and
oropharyngeal cancers result in increased overall survival, disease-
free survival, locoregional control and reduced recurrence.
Secondary objective
To determine the implication of treatment modalities in terms
of morbidity (quality of life, complications, harms and adverse
events) and Utilization of the Health care services (costs, hospital
days of treatment).
M E T H O D S
Criteria for considering studies for this review
Types of studies
RCTs comparing different surgical treatmentmodalities or trials of
other treatment interventions with and without surgery including
radiotherapy and chemotherapy. We anticipated that there would
be no studies comparing surgery with placebo (although if there
were such studies they would have been included).
Types of participants
People with oral cancer as defined by the International Classifica-
tion of Diseases for Oncology (ICD-O) codes as C01-C02, C03,
C04, C05-C06 (oral cavity) and cancer of the oropharynx (ICD-
O: C09, C10). We excluded hypopharynx (ICD-O: C13), na-
sopharynx (ICD-O: C11), larynx (ICD-O: C32) and cancers of
the lip (ICD-O: C00) (WHO 1990).
We included studies of HNC with cases of oral cancer (as long
as at least 50% of participants had oral cavity or oropharyngeal
cancer, or data for these cancers alone are available separately).
Cancers were primary SCCs arising from the oral mucosa. We in-
cluded histological variants of SCCs (e.g. adenosquamous, verru-
cous, basaloid, papillary). Although they are known to have differ-
ing natural history to most conventional SCCs, they have a com-
mon aetiology, incidence is low and they are generally managed
in the same way. We included carcinoma in situ.
We excluded epithelial malignancies of the salivary glands, odon-
togenic tumours, all sarcomas and lymphomas as these have a dif-
ferent aetiology and are managed differently.
Types of interventions
Surgical treatment of the primary tumour is typically one of the
primary treatment interventions. Surgical treatment could have in-
cluded traditional scalpel-based surgery, laser cutting or ablation,
or harmonic scalpel. We included trials that compared surgical
treatment with another surgical intervention; different treatment
modalities such as radiotherapy, chemotherapy, immunotherapy/
biotherapy with or without surgery; any combinations were con-
sidered providing they were compared to surgery in at least one
arm of the study. We did not consider salvage or palliative surgery.
We included studies that carried out surgical treatment of the neck
lymph nodes (cervical lymph nodes) before, after or at the same
time as surgical treatment of the primary tumour. We did not
consider studies when there was surgical treatment of the cervical
lymph nodes but no treatment of the primary tumour. We in-
cluded studies concerned with cervical lymph node management
in the surgical treatment of the primary tumour.
The treatments received and compared must have been the pri-
mary treatment for the tumour and participants should not have
received any prior intervention other than diagnostic biopsy.
Types of outcome measures
As we did not expect many data, we planned to report outcomes
at all time points reported, other than for ’time to event’ data as
the hazard ratios (HR) would be used to summarise this.
Primary outcomes
• Overall survival (or total mortality) (disease-related
mortality will also be studied, if possible).
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• Disease-free survival (or new disease, progression and
mortality).
• Locoregional recurrence.
• Recurrence.
Secondary outcomes
• Harms associated with treatment.
• Quality of life.
• Direct and indirect costs to patients and health services.
• Participant satisfaction.
Search methods for identification of studies
For previous versions of this review, searches were conducted as
part of a series of Cochrane Reviews on the treatment modali-
ties for treating oral cavity and oropharyngeal cancer. The reviews
were divided into four themes: surgery, chemotherapy, radiother-
apy and immunotherapy/targeted therapies. A search strategy was
developed that would encompass three of the four broad themes
simultaneously (surgery, chemotherapy, radiotherapy, see Bessell
2011 for details of the search strategy). From 2011 onwards, we
conducted a more specific search for the surgery theme.
Electronic searches
Cochrane Oral Health’s Information Specialist conducted system-
atic searches in the following databases for RCTs and controlled
clinical trials. There were no language, publication year or publi-
cation status restrictions.
• Cochrane Oral Health’s Trials Register (searched 20
December 2017; Appendix 1);
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2017, Issue 11) in the Cochrane Library (searched
20 December 2017; Appendix 2);
• MEDLINE Ovid (1946 to 20 December 2017; Appendix
3);
• Embase Ovid (1980 to 20 December 2017; Appendix 4).
Subject strategiesweremodelled on the search strategy designed for
MEDLINE Ovid. Where appropriate, they were combined with
subject strategy adaptations of the highly sensitive search strategy
designed byCochrane for identifying RCTs and controlled clinical
trials as described in theCochrane Handbook for Systematic Reviews
of Interventions Chapter 6 (Lefebvre 2011).
Searching other resources
We searched the following trial registries for ongoing studies:
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov ( clinicaltrials.gov; searched 20 December
2017; Appendix 5);
• World Health Organization International Clinical Trials
Registry Platform ( apps.who.int/trialsearch; searched 20
December 2017; Appendix 6).
When necessary, we contacted authors of key papers and abstracts
to request further information about their trials.
We searched the reference lists of included studies and relevant
systematic reviews for further studies.
We did not perform a separate search for adverse effects of inter-
ventions used; we considered adverse effects described in included
studies only.
Data collection and analysis
Selection of studies
At least two review authors (from HW, VB, AMG, DC, MM)
independently scanned the titles and abstracts (when available) of
all reports identified through the electronic searches. The search
was designed to be sensitive and include controlled clinical trials;
these were filtered out early in the selection process if theywere not
randomised. As studies involving oral cancer are often included
with those of the head and neck, we undertook a broad search
to include all possible studies (Figure 1). For studies appearing to
meet the inclusion criteria, or forwhich therewere insufficient data
in the title and abstract to make a clear decision, we obtained the
full report.We excluded data from conference abstracts alone from
the review. Two review authors independently assessed full reports
obtained from the searches to establish whether the studiesmet the
inclusion criteria or not. We resolved disagreements by discussion
or by consulting a third review author if necessary. We recorded
studies rejected at this or subsequent stages in the Characteristics
of excluded studies table, and recorded our reasons for exclusion.
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Figure 1. Study flow diagram.
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Data extraction and management
At least two review authors independently extracted data from in-
cluded studies. The data extraction forms were piloted on several
papers and modified as required before use. We discussed any dis-
agreements and a third review author was consulted where nec-
essary. However, group discussion was often required following
data extraction due to the complexity of the data presented.When
necessary, we contacted study authors for clarification or missing
information.
For each trial, we recorded the following data.
• Year of publication, country of origin and source of study
funding.
• Details of the participants including demographic
characteristics and criteria for inclusion and exclusion,
proportion with oral cavity and oropharyngeal cancer.
• Details of the type of intervention, timing and duration.
• Details of the outcomes reported, including method of
assessment, and time intervals.
We planned to include HNC trials with only combined data (i.e.
no outcome data available by primary tumour site) where greater
than 50% of participants presented with oral/oropharyngeal can-
cer; however, where separate ’pure’ oral/oropharyngeal cancer data
were available for a trial, we extracted and analysed these ’pure’
data and analysed and ignored the combined head and neck data.
Assessment of risk of bias in included studies
At least two review authors independently conducted assessment
of risk of bias in included studies using the Cochrane ’Risk of bias’
tool (Higgins 2011). We assessed six domains for each included
study: sequence generation, allocation concealment, blinding (of
participant, carer, outcome assessor), completeness of outcome
data, selective outcome reporting and other potential sources of
bias. We made an overall risk of bias assessment for each study.
For this systematic review, we assessed risk of bias according to the
following.
• Sequence generation: low risk if use of a random number
table, computerised system, central randomisation by statistical
co-ordinating centre, randomisation by an independent service
using minimisation technique, permuted block allocation or
Zelan technique. If the paper merely stated randomised or
randomly allocated with no further information, we assessed this
as being unclear.
• Allocation concealment: low risk if centralised allocation
including access by telephone call or fax, or pharmacy-controlled
randomisation, sequentially numbered, sealed, opaque envelopes.
• Blinding: as mortality is the primary outcome that is most
frequently and reliably reported, we decided to assess all trials as
being at low risk of bias for this domain.
• Outcome data: outcome data were considered complete if
all participants randomised were included in the analysis of the
outcome(s). However, in trials of treatment for cancer this is
rarely the case. Trials where less than 10% of those randomised
were excluded from the analysis, and where reasons for
exclusions were described for each group, and where both
numbers and reasons were similar in each group, were assessed at
low risk of bias due to incomplete outcome assessment. Where
postrandomisation exclusions were greater than 10%, or reasons
were not given for exclusions from each group, or where rates
and reasons were different for each group, we assessed the risk of
bias due to (in)complete outcome data as unclear.
• Selective outcome reporting: we assessed a trial at low risk
of bias due to selective outcome reporting if the outcomes of
interest that were described in the methods section were
systematically reported in the results section. Where reported
outcomes did not include those outcomes specified or expected
in trials of treatments for oral cancer, or where additional
analyses were reported, we assessed this domain as unclear.
• Other bias: we noted examples of potential sources of bias
such as imbalance in potentially important prognostic factors
between the treatment groups at baseline, or the use of a
cointervention in only one group (e.g. nasogastric feeding). If
information was not available about the intervention groups at
baseline, we assessed studies as being at unclear risk of bias.
Measures of treatment effect
The primary outcome most frequently and reliably reported was
total mortality, expressed as an HR. An HR provides an estimate
of the ratio of the hazard rates, for a particular event, between
the experimental group and a control group over the duration of
the entire study. For overall survival, the event of interest is death
(total mortality). It is acknowledged that it is preferable to talk
in terms of overall survival; however, statistically, the estimate of
effect is the HR of death.
We entered these data into the meta-analysis using the inverse
variance method. If studies did not quote HRs, we calculated the
log HR and the standard error from the available summary statis-
tics or Kaplan-Meier curves, according to the methods proposed
by Parmar and colleagues (Parmar 1998), or requested these data
from authors.
For dichotomous outcomes, we expressed the estimates of effect of
an intervention as risk ratios (RR) together with 95% confidence
intervals (CI). Dichotomous data were only used for primary out-
comes where HRs were unavailable or could not be calculated.We
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planned to combine data of similar follow-up periods.
Assessment of heterogeneity
We conducted meta-analyses only if there were studies of similar
comparisons reporting the same outcome measures. We assessed
the significance of any discrepancies in the estimates of the treat-
ment effects from the different trials using Cochrane’s test for het-
erogeneity and the I² statistic, and we investigated any heterogene-
ity.
Data synthesis
We conducted meta-analyses only if there were studies of similar
comparisons reporting the same outcomemeasures.We combined
RR for dichotomous data, and HRs for survival data, using ran-
dom-effect models.
Subgroup analysis and investigation of heterogeneity
Due to the different natural history and treatment regimens for
oral cavity and oropharyngeal cancers, we planned to analyse these
cancer types separately, if possible.
Sensitivity analysis
Weplanned sensitivity analysis (to examine the effects of randomi-
sation, allocation concealment, blinded outcome assessment (if
appropriate) and quality of follow-up/completeness of data set),
but there were insufficient data.
R E S U L T S
Description of studies
Results of the search
We identified 6929 research papers through the electronic search-
ing for this update, after the removal of duplicates (Figure 1).
Screening of the titles and abstracts resulted in the identification
of 26 potentially relevant trials for inclusion in the review. We re-
trieved full-text copies of these articles. Further assessment of the
papers resulted in five trials being included in this update of the
review. Four of these trials were newly identified (Guo 2014; Iyer
2015;Mehanna 2017; Rastogi 2018), and one trial had previously
been identified (D’Cruz 2015).
Included studies
Of the 12 trials included in the review, five were multicentred,
with the number of centres ranging from two to 37. Three tri-
als were undertaken in India (D’Cruz 2015; Fakih 1989; Rastogi
2018), two in Brazil (BHNCSG 1998; Kligerman 1994), two in
China (Guo 2014; Yuen 2009), two in the UK (Mehanna 2017;
Robertson 1998), one in centres across Europe (Austria, Ger-
many and Switzerland) (Bier 1994), one in France (Vandenbrouck
1980), and one in Singapore (Iyer 2015). Twenty-four trials, pre-
viously included in this review, have now been excluded, because
they better fit in the other oral cancer treatment reviews (see
Characteristics of excluded studies for details). Three trials re-
quired personal communication with the authors of the papers for
retrieval of extra information (Kligerman 1994; Mehanna 2017;
Robertson 1998).
Participants
Participants were recruited over periods ranging from two years
to 11 years, with the earliest recruitment commencing in 1966
(Vandenbrouck 1980). A total of 2300 participants were randomly
allocated to treatments and 2090 were included in the outcome
evaluations. Most of the participants (2148) had oral cavity tu-
mours and the remainder had oropharyngeal tumours.
All included trials reported tumour extent (TNM), four of which
includedparticipantswithT1 toT2 tumours (D’Cruz 2015; Fakih
1989; Kligerman 1994; Yuen 2009), two with T2 to T4 tumours
(BHNCSG 1998; Robertson 1998), two with T1 to T3 tumours
(Rastogi 2018; Vandenbrouck 1980), and three with T1 to T4
tumours (Guo 2014; Iyer 2015; Mehanna 2017). In seven of the
trials, participants had clinically negative neck nodes (BHNCSG
1998; D’Cruz 2015; Fakih 1989; Kligerman 1994; Rastogi 2018;
Vandenbrouck 1980; Yuen 2009), three trials included partici-
pants with neck nodes clinically staged as N0-2 (Guo 2014; Iyer
2015; Robertson 1998), and one trial included participants with
clinically staged N2-3 nodes (Mehanna 2017). The trial by Bier
1994 did not record the tumour stage or node status of the par-
ticipants at trial entry (Table 1).
Of the 12 included trials, eight included recruited participants
with oral cavity cancer only (BHNCSG 1998; Bier 1994; D’Cruz
2015; Fakih 1989; Kligerman 1994; Rastogi 2018; Vandenbrouck
1980; Yuen 2009); two included participants with oral cavity or
oropharyngeal cancer (Guo 2014; Robertson 1998); one included
participants with cancer of the oral cavity, oropharynx, hypophar-
ynx, larynx and maxillary sinus (Iyer 2015); and one included
participants with cancer of the oral cavity, tonsil, base of tongue,
supraglottis and glottis or subglottis (Mehanna 2017).
Interventions
None of the included trials compared different surgical approaches
to the excision of the primary tumour.
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Nine trials of participants with oral cavity cancers compared either
different surgical techniques for management of the lymph nodes
in the neck or different timing for removal of the lymph nodes
in the neck (BHNCSG 1998; Bier 1994; D’Cruz 2015; Fakih
1989; Guo 2014; Kligerman 1994; Rastogi 2018; Vandenbrouck
1980; Yuen 2009). Five trials compared the timing of neck dissec-
tion; either elective neck dissection at the same time as excision of
the primary tumour or therapeutic neck dissection (delayed un-
til nodes became clinically positive) (D’Cruz 2015; Fakih 1989;
Kligerman 1994; Vandenbrouck 1980; Yuen 2009). Kligerman
1994 used a supraomohyoid (SOH) approach for the elective neck
dissection in a group of participants with clinically negative neck
nodes compared with a therapeutic neck dissection if the nodes
became clinically positive. Yuen 2009 compared an elective selec-
tive neck dissection at the time of glossectomy with glossectomy
alone plus therapeutic neck dissection if nodes became clinically
positive. Fakih 1989 used elective RND at the same time as re-
section of the primary tumour in a group with clinically negative
neck nodes. Vandenbrouck 1980 compared elective RND within
two months of resection of the primary tumour with therapeutic
neck dissection. D’Cruz 2015 compared a selective neck dissec-
tion with a modified therapeutic neck dissection.
Four trials compared different types of neck dissection surgery at
the time of removal of the primary tumour (BHNCSG 1998; Bier
1994; Guo 2014; Rastogi 2018). In the trial by Bier 1994, both
groups had a radical resection of the primary tumour. One group
had RND at the same time as resection and the other had selective
neck dissection surgery. The Brazilian Study group compared a
modified RND with a SOH neck dissection in conjunction with
resection of the primary tumour (BHNCSG 1998). Rastogi 2018
compared superselective neck dissection with SOH neck dissec-
tion in conjunction with resection of the primary tumour. Guo
2014 compared SOHneck dissection withmodified RND in con-
junction with resection of the primary tumour.
The trial by Robertson 1998 compared surgery followed by radio-
therapy with radiotherapy alone in a group of participants with
either oral cavity or oropharyngeal cancer. Iyer 2015 compared
surgery and adjuvant radiotherapy with concurrent chemoradio-
therapy. Mehanna 2017 compared positron-emission tomogra-
phy-computed tomography (PET-CT) guided watch and wait
policy (with neck dissection undertaken only if no/incomplete re-
sponse to chemoradiotherapy identified) with planned neck dis-
section before or after radical chemoradiotherapy for locally ad-
vanced head and neck SCC.
Outcome measures
The duration of follow-up in the included trials ranged from ap-
proximately 15 months (Bier 1994) to 122 months (Yuen 2009).
All trials except one reported either total mortality or overall sur-
vival (Yuen 2009), but not all provided data in a form suitable
for inclusion in meta-analysis. Six trials reported disease-free sur-
vival (Bier 1994; D’Cruz 2015; Fakih 1989; Kligerman 1994;
Vandenbrouck 1980; Yuen 2009), and seven trials reported re-
currence (BHNCSG 1998; D’Cruz 2015; Fakih 1989; Kligerman
1994; Rastogi 2018; Robertson 1998; Yuen 2009).
Five trials mentioned harms/adverse events (BHNCSG 1998;
D’Cruz 2015; Guo 2014; Mehanna 2017; Robertson 1998).
BHNCSG 1998 reported the total number of adverse events in
each group but not the number of participants affected. Two trials
reported the percentages of participants in each group who expe-
rienced adverse effects (D’Cruz 2015; Robertson 1998). One trial
reported quality-adjusted-life-years (QALYs), costs and harms/ad-
verse events (Mehanna 2017). One trial reported hospital days of
treatment (Guo 2014).
Excluded studies
We excluded 24 trials that were previously included in this re-
view because they better fit in the other oral cancer treatment re-
views. Four previously included trials (Ang 2001; Lawrence 1974;
Sanguineti 2005; Terz 1981) are now included in the radiother-
apy review (Glenny 2010); 17 previously included trials (Bernier
2004; Cooper 2004; Lam 2001; Laramore 1992; Licitra 2001;
Luboinski 1985; Maipang 1995; Mohr 1994; Paccagnella 1994;
Rao 1991; Rentschler 1987; Richard 1991; Schuller 1988; Szabo
1999; Szpirglas 1978; Volling 1999; Weissler 1992) are now in-
cluded in the chemotherapy review (Furness 2011), and three pre-
viously included trials are being considered for inclusion in the
immunotherapy review, which is currently being prepared. One
trial was excluded from this review because less than 50% of the
participants had oral cavity or oropharyngeal cancer and their data
could not be extracted separately (Hintz 1979a).
Risk of bias in included studies
Allocation
Four of the included trials reported adequate sequence generation
methods (D’Cruz 2015; Fakih 1989; Mehanna 2017; Robertson
1998); in the remaining eight trials, the methods of sequence gen-
eration were unclear. Two trials reported adequate allocation con-
cealment (Robertson 1998; Vandenbrouck 1980), but only one
trial was assessed as being at low risk of bias in both of these do-
mains (Robertson 1998).
Blinding
Blinding of participants and clinicians is not feasible in surgical
trials, but blinding of outcome assessment is both possible and
desirable. However, as mortality is the primary outcome that is
most frequently and reliably reported, a decision was made to
assess all trials as being at low risk of bias for this domain.
14Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Incomplete outcome data
We assessed nine of the included trials at low risk of bias with
regard to incomplete outcome data because all the randomised
participants were adequately accounted for in the outcome evalu-
ation (BHNCSG 1998; Guo 2014; Iyer 2015; Kligerman 1994;
Mehanna 2017; Rastogi 2018; Robertson 1998; Vandenbrouck
1980; Yuen 2009). Of the remaining trials, we assessed two at
high risk with regard to this domain (Bier 1994; Fakih 1989), and
one at unclear (D’Cruz 2015). Both Bier 1994 and Fakih 1989
presented an interim analysis of a subgroup of participants and
the final analysis has not been published as far as we are aware.
In both of these trials, it was unclear how many participants were
randomly allocated to each intervention group, and how many
in each group were subsequently excluded from the analysis or
analysed in a different group from that to which they were origi-
nally allocated (or both). It is likely that those excluded from the
analysis (because they refused surgery or had extracapsular rupture
during surgery) had a different outcome from those included in
the analysis.
Selective reporting
We assessed 11 of the included trials as free of selective reporting
bias as they reported on expected, clinically important outcomes.
Yuen 2009 did not report total mortality or overall survival, so was
at high risk of bias for this domain.
Other potential sources of bias
We assessed eight trials at low risk of other bias because the inter-
vention groups appeared to be similar at baseline and there were
no other sources of bias (BHNCSG 1998; D’Cruz 2015; Guo
2014; Iyer 2015; Mehanna 2017; Rastogi 2018; Vandenbrouck
1980; Yuen 2009).
Three trials provided no information regarding the baseline char-
acteristics of participants in each group, and so these trials were
at unclear risk of other bias (Bier 1994; Fakih 1989; Kligerman
1994).
We assessed Robertson 1998 at high risk of other bias because,
although planned recruitment was 350 participants, this trial was
stopped after only 35 participants were recruited because clinicians
felt it was unethical to continue. While appropriate procedures
were followed and an interim analysis was conducted and reported,
it is not clear from this report whether a priori stopping rules were
in place. Additionally, more than half of the participants in this
trial did not receive radiotherapy as planned due to problems with
faulty equipment. It is likely that this would have had a greater
effect on the outcomes the of radiotherapy-only arm of the trial.
Overall risk of bias
A summary of the ’Risk of bias’ assessment is presented in Figure
2. Overall, we assessed four studies at high risk of bias (Bier
1994; Fakih 1989; Robertson 1998; Yuen 2009), and eight tri-
als at unclear risk of bias (BHNCSG 1998; D’Cruz 2015; Guo
2014; Iyer 2015; Kligerman 1994; Mehanna 2017; Rastogi 2018;
Vandenbrouck 1980), for all of the outcomes evaluated.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Effects of interventions
See: Summary of findings for the main comparison Elective
neck dissection versus therapeutic (delayed) neck dissection;
Summary of findings 2 Elective radical neck dissection versus
elective selective neck dissection; Summary of findings 3
Surgery plus radiotherapy versus radiotherapy alone; Summary
of findings 4 PET-CT following chemoradiotherapy versus
planned neck dissection either before or after chemoradiotherapy;
Summary of findings 5 Surgery plus adjuvant radiotherapy versus
chemotherapy; Summary of findings 6 Supraomohyoid neck
dissection versus modified radical neck dissection; Summary of
findings 7 Super-selective neck dissection versus selective neck
dissection
Comparison 1: elective neck dissection versus
therapeutic (delayed) neck dissection
See Summary of findings for the main comparison.
Five trials compared the timing of the neck dissection; either at
the same time as resection of the primary tumour or as a separate
procedure subsequent to resection of the primary, with dissection
of the neck nodes being undertaken only after there was clinical
evidence of disease in the neck nodes (D’Cruz 2015; Fakih 1989;
Kligerman 1994; Vandenbrouck 1980; Yuen 2009). All partici-
pants had oral cavity cancers, specifically tongue or floor of mouth
tumours and clinically negative neck nodes on study entry.
Fakih 1989 and Vandenbrouck 1980 performed classical RND
procedures and pooled data after one year (Fakih 1989) and three
years (Vandenbrouck 1980) of follow-up. D’Cruz 2015 and Yuen
2009 performed selective neck dissection of level I to III nodes
with D’Cruz 2015 reporting data at three years. Kligerman 1994
used a SOH elective neck dissection procedure, and reported data
after 3.5 years of follow-up. Fakih 1989 and Yuen 2009 was at
overall high risk of bias andKligerman 1994, Vandenbrouck 1980,
and D’Cruz 2015 were at unclear overall risk of bias.
Overall survival (or total mortality)
Two trials presented overall survival data as HRs (D’Cruz 2015;
Vandenbrouck 1980) and two trials as RRs (Fakih 1989 at one
year; Vandenbrouck 1980 at three years). The meta-analysis for
the HRs showed no evidence of a difference between the inter-
ventions (Analysis 1.1; very low-certainty evidence)). We were un-
able to pool the binary data due to different follow-up periods.
Fakih 1989 found no evidence of a difference between elective
RND and therapeutic neck dissection at one-year follow-up (very
low-certainty evidence); however, Kligerman 1994, where elective
surgery was the less extensive SOH, found a difference in overall
survival after 3.5 years of follow-up, favouring elective SOH neck
dissection compared to therapeutic neck dissection (Analysis 1.2;
very low-certainty evidence).
Disease-free survival (or new disease, progression and
mortality)
Three trials reported the data for disease-free survival as HRs
(D’Cruz 2015; Kligerman 1994; Vandenbrouck 1980), and two
trials as RRs (Fakih 1989 at one year; Vandenbrouck 1980 at
three years). The pooled HR showed no evidence of a difference
between elective neck dissection and therapeutic neck dissection
(HR 0.73, 95% CI 0.25 to 2.11; Analysis 1.3; very low-certainty
evidence). One study provided very low-certainty evidence of a
benefit from elective SOHneck dissectionwhen compared to ther-
apeutic neck dissection (HR 0.32, 95% CI 0.12 to 0.84; Analysis
1.3) (Kligerman 1994). The binary data showed no evidence of a
difference between the interventions (Analysis 1.4; very low-cer-
tainty evidence).
Locoregional recurrence
Four trials reported binary data on locoregional recurrence
(D’Cruz 2015; Fakih 1989; Kligerman 1994; Vandenbrouck
1980), but the data were not suitable for meta-analysis due to the
differences between studies in the type of surgery and the duration
of follow-up (Analysis 1.5; very low-certainty evidence). The re-
sults were mixed, with three trials suggesting neither intervention
was superior, while the study evaluating elective SOHneck dissec-
tion concluding this approach may reduce locoregional recurrence
more than therapeutic delayed ND.
Recurrence
Two trials reported recurrence rates at different sites, but num-
bers were too small to determine whether there may have been
a difference between the groups in rate of recurrence of either a
second primary tumour or distant metastases (data not shown)
(Vandenbrouck 1980; Yuen 2009).
Secondary outcomes
In D’Cruz 2015, 6.6% of the elective-surgery participants showed
adverse events, while 3.6% of participants in the therapeutic-
surgery group reported adverse events. These included neck
haematoma, chyle leak, oral bleeding, postoperative infection and
anaphylaxis. None of the other trials reported on adverse events.
None of the trials reported on quality of life, costs or any measure
of participant satisfaction.
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Comparison 2: elective radical neck dissection versus
elective selective neck dissection
See Summary of findings 2.
Two trials compared neck dissection surgery of differing extent
(BHNCSG 1998; Bier 1994). There were differences between the
two studies with regard to participant characteristics at baseline
and surgical procedures so meta-analysis was not undertaken.
BHNCSG 1998 compared a modified classical neck dissection
procedure with accessory nerve preservation, to a SOH neck dis-
section to achieve a compartmental excision of levels I to III neck
nodes in 148 participants with T2 to T4 primary lesions in the oral
cavity and clinically negative nodes. Frozen sections were carried
out on the nodes during surgery and three participants in the SOH
group who had histologically positive nodes then underwent the
modified classical neck dissection instead. This trial was at overall
unclear risk of bias.
In Bier 1994, 104 participants with either clinically negative or
positive but movable neck nodes were randomised to either RND
or a selective neck dissection where the platysma, sternocleidomas-
toid muscle, internal jugular vein and accessory nerve were left in
place. Primary tumours were in the oral cavity and the study was
at overall high risk of bias.
Overall survival (or total mortality)
There was no evidence of a difference in overall survival (Analysis
2.1; very low-certainty evidence).
Disease-free survival (or new disease, progression and
mortality)
Only Bier 1994 reported disease-free survival and there was no
evidence of a difference (Analysis 2.2; very low-certainty evidence).
Locoregional recurrence
Neither trial reported locoregional recurrence.
Recurrence
Only BHNCSG 1998 reported recurrence as binary data at five
years, and there was no evidence of a difference in disease recur-
rence (Analysis 2.3; very low-certainty evidence).
Secondary outcomes
BHNCSG 1998 reported the following adverse effects: flap necro-
sis, wound infection, fistula, vascular rupture, haematoma, seroma
and chyle fistula. There were no complications in 45/76 partici-
pants in the modified RND group and none in 54/72 participants
in the SOH neck dissection group. There were two postoperative
deaths in the modified RND group and one in the SOH neck
dissection group.
Neither trial reported other secondary outcomes.
Comparison 3: surgery plus radiotherapy versus
radiotherapy alone
See Summary of findings 3.
One trial compared surgery plus postoperative radiotherapy with
radiotherapy alone (Robertson 1998). Participants in the surgery
group hadwide local excision of the primary tumour together with
either a RND or a more selective neck dissection at the discretion
of the surgeon. It was planned to accrue 175 participants, with
oral cavity or oropharyngeal cancer (neck nodes clinically staged
as N0 to 2) to each arm of the trial but after 35 participants had
been recruited the trial was stopped due to the high death rate in
the radiotherapy alone arm.
Overall survival (or total mortality)
Data in Analysis 3.1 are from an interim analysis of 35 participants
after 23 months and showed an HR for total mortality of 0.24
(95%CI 0.10 to 0.59), favouring the surgery group. This estimate
should be interpreted with extreme caution for several reasons.
The authors stated that “the difference in survival is likely to be
inflated” due to the small number of participants in the analysis,
the fact that only 41% of participants in the radiotherapy only arm
received their radiotherapy as planned due to problems with faulty
machines, and that there were several other protocol violations in
the trial. In the surgery plus radiotherapy arm, 50% of the partic-
ipants received radiotherapy as planned, but 12% of participants
received neither surgery to the mandible nor neck dissection.
Disease-free survival (or new disease, progression and
mortality)
The trial did not report this outcome.
Locoregional recurrence
The trial did not report locoregional recurrence.
Recurrence
The trial did not report recurrence.
Secondary outcomes
Therewere the following severe acute adverse effects in both groups
(Robertson 1998): subcutaneous fibrosis, telangiectasia (1 cm² to
4 cm²), and moderate to severe oedema, xerostomia, trismus and
dysphagia. Subcutaneous fibrosiswasmore prevalent in the surgery
plus radiotherapy group (P = 0.042), but the prevalence of other
adverse effects appeared to be similar in each group.
The trial did not report other secondary outcomes.
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Comparison 4: PET-CT following chemoradiotherapy
versus planned neck dissection either before or after
chemoradiotherapy
See Summary of findings 4.
One trial at overall unclear risk of bias compared PET-CT-guided
surveillance (with neck dissection only if no response or incom-
plete response to chemoradiotherapy) to planned neck dissection
(either before or after chemoradiotherapy) in participants with
stage N2 or N3 disease (Mehanna 2017). The study recruited 564
participants.
Overall survival (or total mortality)
There was no evidence of a difference in total mortality be-
tween PET-CT ’watch-and-wait’ and planned neck dissections
(HR 0.92, 95% CI 0.65 to 1.31; Analysis 4.1; very low-certainty
evidence).
Disease-free survival (or new disease, progression and
mortality)
There were limited data that wewere unable to use.Mehanna2017
reported that “Disease-specific mortality and mortality from other
causes did not differ significantly between the two groups (P = 0.80
and 0.41, respectively, according to Gray’s test for differences).”
Locoregional recurrence
There were limited data that we were unable to use. Mehanna
2017 reported that “The 2-year rate of locoregional control was
91.9%(95%CI, 88.5 to 95.3) in the surveillance group and91.4%
(95% CI, 87.8 to 95.0%) in the planned-surgery group. In the
latter group, the 2-year rate of locoregional control was 90.4%
(95% CI, 86.0 to 94.7) among patients who underwent neck
dissection after chemoradiotherapy and 94.8% (95% CI, 89.0
to 100) among patients who underwent neck dissection before
chemoradiotherapy.”
Recurrence
There were limited data that wewere unable to use.Mehanna2017
reported that “Documented recurrence in the nodes only (without
concurrent disease in the primary site) occurred in 1 patient in the
planned-surgery group and in 3 patients in the surveillance group.
Distant metastases were identified in 23 patients in the planned-
surgery group and in 21 patients in the surveillance group.”
Secondary outcomes
There were 22 surgical complications after neck dissection in
the surveillance group compared with 83 in the planned-surgery
group.
Mehanna 2017 assessed quality of life using EORTC QLQ-C30
questionnaire. There was a small difference in global health status
scores in favour of the surveillance group at six months after ran-
domisation relative to planned-surgery group (mean change 4.94;
P = 0.09). This difference narrowed at 12 months (mean change
3.03; P = 0.09) and was no longer apparent at 24 months (mean
change -0.81; P = 0.85).
There was an economic evaluation undertaken consisting of two
components: a within-trial analysis and a decision analytic model.
The primary analysis was conducted from a National Health Ser-
vice (NHS) secondary care perspective (i.e. including NHS hos-
pital costs). PET-CT guided surveillance was more cost effective
than planned neck dissection. Compared with planned neck dis-
section, PET-CT surveillance produced an incremental net health
benefit of 0.16 quality-of-life years (QALYs) (95% CI 0.03 to
0.28) over the trial period, and 0.21 QALYs (95% CI to 0.41 to
0.85) over the modelled lifetime horizon.
The trial reported none of the other secondary outcomes.
Comparison 5: surgery plus adjuvant radiotherapy
versus chemotherapy
See Summary of findings 5.
One trial at overall unclear risk of bias compared neck dissection
surgery plus adjuvant radiotherapy versus chemotherapy in 119
participants with histologically confirmed respectable stage III/IV
head and neck SCC (excluding nasopharynx and salivary gland
SCC) (Iyer 2015). The median follow-up for surviving partici-
pants was 13 years.
Overall survival (or total mortality)
The study report stated, “For the oral cavity, survival was signifi-
cantly better in patients who underwent surgery andRT compared
with the CRT group.” However, there were no useable data.
Disease-free survival (or new disease, progression and
mortality)
The study reported that disease-free survival was statistically sig-
nificant in favour of the surgery group (P = 0.038), but there were
no useable data.
Locoregional recurrence
The study reported that locoregional recurrence-free survival was
not statistically significant between the groups (P = 0.355), but
there were no useable data.
Recurrence
The study reported that distant recurrent-free survival was not sta-
tistically significant between the groups, but there were no useable
data.
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The study report stated, “The 5-year DSS rates were 68% for the S
[surgery] arm versus 12% for the C [chemotherapy] arm (P5.038)
(Fig. 3a). Similarly, rates of distant metastasis were higher among
patients on the C arm, with 5-year DRFS [distant recurrent-free
survival] rates of 50% compared with 92% for patients on the S
arm (P5.05) (Fig. 3b). However, no statistically significant differ-
ence was observed in locoregional disease recurrence rates between
the treatment arms (P5.355) (Fig. 3c), although there may have
been a trend favoring the S arm.”
Secondary outcomes
The trial reported no secondary outcomes.
Comparison 6: supraomohyoid neck dissection versus
modified radical neck dissection
See Summary of findings 6.
One trial at overall unclear risk of bias compared SOH neck dis-
section versus modified RND (Guo 2014). Participants, with oral
cavity or oropharyngeal cancer, had T1 to T4 tumours with neck
nodes clinically staged as N0 to 2.
Overall survival (or total mortality)
The study reported overall survival/total mortality during the fol-
low-up period (with different follow-up times), so could not be
used for analysis. The study report stated, “During the follow-up
period 113 (35.1%) of the 322 patients died (SOND [supraomo-
hyoid neck dissection]: 53 cases, MRND [modified radical neck
dissection]: 60 cases).
Disease-free survival (or new disease, progression and
mortality)
The study reported data for disease-specific survival but we were
unable to use them in an analysis. The study report stated, ”There
was no significant difference between the SOND [supraomohyoid
neck dissection] group and the MRND [modified radical neck
dissection] group in the 3-year disease-specific survival (DSS) rate
(79.0% vs. 76.9%, P = 0.659).“
The Kaplan Meier survival curve for neck recurrence-free survival
had insufficient information to calculate the HR. The study re-
port stated, ”By the Kaplan-Meier test, the patients in the SOND
[supraomohyoid neck dissection] group had a better 3-year NCR
[neck control rate] than those in the MRND [modified radi-
cal neck dissection] group, but the difference was not significant
(92.6% vs. 87.5%, P = 0.108).“
Locoregional recurrence
The trial did not report locoregional recurrence.
Recurrence
The trial did not report recurrence.
Secondary outcomes
There was some limited information on adverse events in the text.
The study report stated, ”There was a significant difference in the
complication rates between both groups (SOND [supraomohyoid
neck dissection] group vs. MRND [modified radical neck dissec-
tion] group: 13.0%vs. 21.9%, P=0.040). Themost frequent com-
plication was wound infection.“ The report summarised other sig-
nificant complications. The study assessed University ofWashing-
ton Quality of Life Questionnaire (UW-QOL) scores for all dis-
ease-free survivors at one year after treatment (Deleyiannis 1997),
scores from nine disease-specific domains appeared to show that
SOH neck dissection was superior to modified RND in the do-
mains of pain relief (78.8% versus 75.2%; P = 0.013) and shoulder
function (81.1% versus 68.1%; P < 0.001), but not in any of the
other domains.
Comparison 7: selective neck dissection versus super-
selective neck dissection
See Summary of findings 7.
One trial at overall unclear risk of bias compared selective neck
dissection versus super-selective neck dissection in participants
with oral cavity cancer (T1 to T3 tumours; clinically negative neck
nodes) (Rastogi 2018).
Overall survival (or total mortality)
The study did not report this outcome.
Disease-free survival (or new disease, progression and
mortality)
The study did not report this outcome.
Locoregional recurrence
The study investigated locoregional recurrence for 2.5 years. Sur-
vival analysis (rate of recurrence) was measured using the Kaplan-
Meier model (survival analysis regression model), however HRs
could not be calculated from the data provided. The study report
stated, ”the P value by Kaplan-Meier survival analysis was less than
.05. Therefore, the SSND (super selective) group showed a lower
rate of recurrence compared with the SND (selective group (P <
.5).“
Recurrence
The study did not report recurrence.
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Secondary outcomes
The study analysed data for shoulder morbidity subjectively and
objectively. The results for both measures showed less shoulder
morbidity and improved quality of life for superselective neck
dissection compared with selective neck dissection. Only P values
were presented so we were unable to use the data provided.
The study authors performed subjective analysis measuring shoul-
der morbidity using the Neck Dissection Quality of Life (ND-
QOL) questionnaire. Data showed that the mean score for the su-
per-selective neck dissection group (30.4) was significantly higher
(P = 0.01) than for the selective neck dissection group (19.4).
The study authors stated that quality of life for the super-selective
neck dissection group was significantly better than the selective
neck dissection group based on the outcome of the ND-QOL
questionnaire. There were no other data presented to confirm this
position other than the scores on the ND-QOL questionnaire.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Radical neck dissection versus selective neck dissection
Patient: adults with oral or oropharyngeal cancer
Setting: inpat ient
Intervention: elective radical neck dissect ion
Comparison: elect ive select ive neck dissect ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Assumed risk Corresponding risk
Selective neck dissec-
tion
Radical neck dissec-
tion
Total mortality - - - 252
(2)
⊕©©©
Very lowa,b
HR f rom 2 trials, but
unable to pool data as
dif ferent surgical pro-
cedures. Neither trial in-
dicated that mortality
was dif ferent for the 2
intervent ions
New disease, progres-
sion or mortality
(follow-up: 5 years)
500c per 1000 326 per 1000
(182 to 537)
HR 0.57
(0.29 to 1.11)
104
(1)
⊕©©©
Very lowb,d
These data were f rom
the HR for disease-f ree
survival.
1 study, indicat ing no
dif ference between the
intervent ions.
250c per 1000 151 per 1000 (80 to
273)
Locoregional recur-
rence
- - - - - Not reported
Recurrence
(5 years)
180e per 1000 213 per 1000
(118 to 370)
RR 1.21
(0.63 to 2.33)
143
(1)
⊕©©©
Very lowb,f,g
1 study, indicat ing no
dif ference between the
intervent ions.
2
2
In
te
rv
e
n
tio
n
s
fo
r
th
e
tre
a
tm
e
n
t
o
f
o
ra
l
a
n
d
o
ro
p
h
a
ry
n
g
e
a
l
c
a
n
c
e
rs:
su
rg
ic
a
l
tre
a
tm
e
n
t
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
8
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Adverse events 1 trial reported the following adverse ef fects: f lap necrosis, wound infect ion, f istula, vascular rupture, haematoma, seroma and chyle f istula. There
were 0 complicat ions in 45 part icipants (59%) in the modif ied radical neck dissect ion group and 0 in 54 part icipants (75%) in the supraomohyoid
neck dissect ion group. There were 2 postoperat ive deaths in the modif ied radical neck dissect ion group and 1 in the supraomohyoid neck dissect ion
group. The other studies did not report adverse events
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; HR: hazard rat io; RR: risk rat io.
GRADE Working Group grades of evidence
High certainty: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate certainty: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low certainty: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low certainty: we are very uncertain about the est imate.
aDowngraded twice, two heterogeneous studies at unclear and high risk of bias.
bDowngraded once for imprecision.
cPurely illustrat ive, unable to f ind any epidemiological est imates.
dDowngraded twice as single study at high risk of bias.
eEstimated f rom BHNCSG 1998.
f SDowngraded once as single study at unclear risk of bias.
g Downgraded twice for imprecision
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Surgery plus radiotherapy versus radiotherapy alone
Patient: adults with oral or oropharyngeal cancer
Setting: inpat ient
Intervention: surgery + radiotherapy
Comparison: radiotherapy alone
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Assumed risk Corresponding risk
Radiotherapy alone Surgery + radiotherapy
Total mortality
(follow-up: 3 years)
500 per 1000 153 per 1000
(67 to 336)
HR 0.24
(0.10 to 0.59)
35
(1)
⊕©©©
Very lowa
These data were f rom
the HR for overall sur-
vival.
1 study, result favour-
ing the surgery group;
however, data were un-
reliable because trial
stopped early and there
were mult iple protocol
violat ions
Disease- free survival - - - - - Not reported
Locoregional recur-
rence
- - - - - Not reported
Recurrence - - - - - Not reported
Adverse events Both groups reported the following severe acute adverse ef fects: subcutaneous f ibrosis, telangiectasia (1-4 cm²), and moderate-to-severe oedema,
xerostomia, trismus and dysphagia. Subcutaneous f ibrosis was reported as more prevalent in the surgery + radiotherapy group (P = 0.042), but the
prevalence of other adverse ef fects appeared to be sim ilar in each group
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* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; HR: hazard rat io.
GRADE Working Group grades of evidence
High certainty: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate certainty: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low certainty: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low certainty: we are very uncertain about the est imate.
aDowngraded three levels as high risk of bias, interim analysis of 35 part icipants af ter 23 months.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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PET-CT following chemoradiotherapy versus planned neck dissection either before or after chemoradiotherapy
Patient: adults with oral or oropharyngeal cancer
Setting: inpat ient
Intervention: PET-CT following chemoradiotherapy
Comparison: planned neck dissect ion either before or af ter chemoradiotherapy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Assumed risk Corresponding risk
Planned neck dissec-
tion
PET-CT
Total mortality
(follow-up: 2 years)
500 per 1000 471 per 1000
(363 to 597)
HR 0.92
(0.65 to 1.31)
564
(1)
⊕©©©
Very lowa,b
These data were f rom
the HR for overall sur-
vival.
1 study, no evidence of
a dif ference in mortality
Disease- free survival - - - - - Outcome not reported
in a usable way.
Locoregional recur-
rence
- - - - - Outcome not reported
in a usable way.
Recurrence - - - - - Outcome not reported
in a usable way.
Adverse events 22 surgical complicat ions in PET-CT group compared with 83 in planned surgery group
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; HR: hazard rat io; PET-CT: positron-emission tomography-computed tomography.
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GRADE Working Group grades of evidence
High certainty: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate certainty: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low certainty: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low certainty: we are very uncertain about the est imate.
aDowngraded once as one study at unclear risk of bias.
bDowngraded twice for imprecision.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Surgery plus adjuvant radiotherapy versus chemotherapy
Patient: adults with oral or oropharyngeal cancer
Setting: inpat ient
Intervention: surgery + adjuvant radiotherapy
Comparison: chemotherapy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of partici-
pants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Assumed risk Corresponding risk
Chemotherapy Surgery + adjuvant
radiotherapy
Total mortality
(follow-up: 2 years)
- - - - - 1 study report
stated, ’’For the oral
cavity, survival was
signif icant ly better
in pat ients who un-
derwent surgery and
RT compared with
the CRT [chemora-
diotherapy] group.‘‘
However, there were
no useable data
Disease- free sur-
vival
- - - - - Reported as stat is-
t ically signif icant in
favour of the surgery
group (P = 0.038)
, but there were no
useable data
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Locoregional recur-
rence
- - - - - Reported as not sta-
t ist ically signif icant
between groups (P
= 0.355), but there
were no useable
data
Recurrence
(5 years)
- - - - - Reported as not sta-
t ist ically signif icant
between the groups,
but there were no
useable data
Adverse events - - - - - Not reported
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95%
conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval.
GRADE Working Group grades of evidence
High certainty: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate certainty: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low certainty: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low certainty: we are very uncertain about the est imate.
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Supraomohyoid neck dissection versus modified radical neck dissection
Patient: adults with oral or oropharyngeal cancer
Setting: inpat ient
Intervention: supraomohyoid neck dissect ion
Comparison: modif ied radical neck dissect ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Assumed risk Corresponding risk
Modified radical neck
dissection
Supraomohyoid neck
dissection
Total mortality
(follow-up: 2 years)
- - - - - 1 study, unable to use
the data.
Disease- free survival - - - - - Outcome not reported
in a usable way.
Locoregional recur-
rence
- - - - - Outcome not reported
in a usable way.
Recurrence
(5 years)
- - - - - Outcome not reported
in a usable way.
Adverse events Signif icant dif f erence in complicat ion rates with lower rates for supraomohyoid procedure
UW-QOL scores for all disease-f ree survivors were assessed at 1 year af ter treatment. Scores f rom 9 disease-specif ic domains appeared to show
that supraomohyoid neck dissect ion was superior to modif ied radical neck dissect ion in the domains of pain relief (78.8% vs 75.2%, P = 0.013) and
shoulder funct ion (81.1% vs 68.1%, P < 0.001), but not in any of the other domains
GRADE Working Group grades of evidence
High certainty: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate certainty: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low certainty: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low certainty: we are very uncertain about the est imate.3
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CI: conf idence interval; UW-QOL: University of Washington Quality of Life Quest ionnaire.
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Super-selective neck dissection versus selective neck dissection
Patient: adults with oral or oropharyngeal cancer
Setting: inpat ient
Intervention: super-select ive neck dissect ion
Comparison: select ive neck dissect ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Assumed risk Corresponding risk
Selective neck dissec-
tion
Super-selective neck
dissection
Total mortality
(follow-up: 2 years)
- - - - - Outcome not reported
Disease- free survival - - - - - Outcome not reported
Locoregional recur-
rence
- - - - - Data not presented in
a useable way. Re-
port concluded that su-
per-select ive procedure
showed a lower rate of
recurrence
Recurrence
(5 years)
- - - - - Outcome not reported
in a usable way.
Adverse events Shoulder morbidity data indicated improvement for super-select ive group, as well as better quality of lif e
GRADE Working Group grades of evidence
High certainty: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate certainty: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low certainty: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low certainty: we are very uncertain about the est imate.32
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D I S C U S S I O N
Summary of main results
This systematic review was undertaken to answer the question
’Does treatment with surgery improve the outcomes for patients
with oral cavity and oropharyngeal cancers?’We included 12RCTs
with a combined total of 2300 randomised participants. Approx-
imately 2148 of these participants had oral cavity cancers. None
of the trials were at overall low risk of bias.
None of the included trials compared different surgical approaches
to the removal of the primary tumour. Five of the included trials
evaluated the timing of neck dissection surgery in the course of
treatment and two included trials evaluated the extent of neck
dissection.
• Comparison 1: elective neck dissection versus therapeutic
(delayed) neck dissection: included five trials that compared
elective neck dissection surgery undertaken at the same time as
excision of the primary tumour with the option of excision of the
primary alone, followed by subsequent neck dissection surgery if
and when neck nodes showed clinical signs of cancer
(therapeutic neck dissection). All participants had oral cavity
cancers, specifically tongue or floor of mouth tumours, and
clinically negative neck nodes. All the evidence was graded as
very low certainty. One trial showed a difference in overall
survival and disease-free survival after three and a half years of
follow-up, favouring elective SOH neck dissection compared to
therapeutic neck dissection. In two trials where the elective
procedure was a RND, there was no difference between the
elective and therapeutic groups with regard to either overall or
disease-free survival. The fourth trial in this group did not report
overall or disease-free survival. There was inconclusive evidence
concerning the effect of elective neck dissection on locoregional
disease recurrence; findings were mixed and the data were
unsuitable for meta-analysis.
• Comparison 2: elective RND versus elective selective neck
dissection: included two trials that compared elective radical
(comprehensive) neck dissection with a selective neck dissection
in participants with oral cavity cancers. One trial included only
participants with clinically negative neck nodes and the other
included those with movable positive neck nodes as well. There
was no evidence from these two trials of a difference in overall
survival between the two types of surgery, and in the single trial
that reported disease-free survival and disease recurrence, there
was no difference between the two types of surgery. All the
evidence was very low certainty.
• Comparison 3: surgery plus radiotherapy versus
radiotherapy alone: involved one trial that compared surgery plus
postoperative radiotherapy and radiotherapy alone, but this trial
was stopped early due to an unacceptably high death rate in the
radiotherapy alone group. There was very low-certainty evidence
of a difference in overall survival favouring the surgery plus
radiotherapy group. These results should be interpreted with
caution because the nature of the interim analysis on 35
participants (10% of planned recruitment) may have inflated the
difference between the groups. Also, there were several protocol
violations (more than half of the participants did not receive
their radiotherapy as planned due to faulty machines), which
may partially explain the poor outcome in the radiotherapy alone
group.
◦ While there was very low-certainty evidence from
these included trials that early or extensive dissection of the
lymph nodes in the clinically negative neck reduced locoregional
recurrence, there was no strong evidence of a difference in overall
survival or disease-free survival. There was no information from
these trials on quality of life of the people who had undergone
the different neck dissection procedures.
• Comparison 4: PET-CT following chemoradiotherapy
versus planned neck dissection either before or after
chemoradiotherapy: involved one trial comparing PET-CT (with
neck dissection only if no/incomplete response to
chemoradiotherapy identified) versus planned neck dissection
(either before or after chemoradiotherapy), there was very low-
certainty evidence of no difference in mortality. The trial did not
provide usable data for the other outcomes.
• Comparison 5: surgery plus adjuvant radiotherapy versus
chemotherapy: involved one trial comparing surgery plus
adjunctive radiotherapy versus chemoradiotherapy. There were
no useable data from this trial.
• Comparison 6: SOH neck dissection versus modified RND
involved one trial comparing SOH neck dissection versus
modified RND. There were no useable data from this trial.
• Comparison 7: selective neck dissection versus super-
selective neck dissection involved one trial that compared super
selective neck dissection versus selective neck dissection. There
were no useable data from this trial.
Overall completeness and applicability of
evidence
This review originally sought to evaluate the benefits of all surgi-
cal treatment modalities used alone or in conjunction with other
treatment regimens such as radiotherapy, or chemotherapy and ra-
diotherapy. However, this led to multiple treatment comparisons
of studies that did not necessarily differ purely on the surgical treat-
mentmethod. This review is one of a series of reviews in oral cancer
looking at surgery, radiotherapy, chemotherapy and immunother-
apy. Therefore, for this update, we modified the protocol for this
review to include only studies that directly compared different
surgical treatment modalities against one another, or compared
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surgery to a different treatment regimen such as radiotherapy, che-
motherapy or immunotherapy. We removed all other studies from
the updated review, and, where appropriate, incorporated them
into the other oral cancer reviews (Furness 2011; Glenny 2010).
The inclusion criteria for this review specified that trials of surgery
where participants had either oral cavity or oropharyngeal cancer
would be included. However, for this update of the review, the
search identified only 12 trials and 2148 of the total of 2300 par-
ticipants in these trials had oral cavity cancers, most commonly
in either the tongue or floor of mouth. The trials, each includ-
ing between 35 and 564 participants, recruited participants over
five decades between 1966 and 2017. There have been signifi-
cant developments in both the surgical and adjuvant treatments
for people with oral cavity cancer since the late 2000s and these
are incompletely evaluated in this systematic review due to the
lack of RCTs in this condition. It is encouraging to note that
there are currently three large trials ongoing that will provide fur-
ther information concerning the benefits and harms of different
surgical options for neck dissection in people with oral cavity
cancer (NCT00571883 (SEND); NCT01334320; Nichols 2013
(formerly NCT01590355)).
Only two of the included studies reported harms or adverse
events to treatment, but neither presented outcomes per person
(BHNCSG 1998; Robertson 1998). Aggressive surgery to remove
the cancer and reduce the risk of recurrence has been associated
with very significant adverse effects on both appearance and func-
tions such as breathing, speech and swallowing. Less-aggressive
surgery, such as selective lymphnode dissection, is associatedwith a
greater risk of recurrence, but preservation of function and appear-
ance. Incorporation of quality of life outcomes into randomised
trials is essential if the true benefits and harms of different types
of surgery are to be evaluated. It is noteworthy that while some of
the trials included in this review reported that some participants
randomly allocated to surgery refused surgical treatment and were
withdrawn from the trials, there was no report of the quality of
life of these people compared to those included in the trials.
We identified no trials of surgery in people with oropharyn-
geal cancer, probably because the current therapeutic approach to
oropharyngeal cancer is either radiotherapy or chemoradiother-
apy. Since the late 2000s, the percentage of people with oropha-
ryngeal cancer who test positive for HPV has increased steadily. It
is now recognised that HPV status of people with oropharyngeal
cancer is an important factor in their prognosis (Adelstein 2009;
Brizel 2011). In updates of this review, we will undertake a sub-
group analysis for the surgical management of HPV-related oral
cavity cancer and the surgical management of non-HPV related
oral cavity cancer, provided there are a sufficient number of trials
reporting this.
Quality of the evidence
The overall certainty of the evidence included in this systematic
review was very low. All of the included trials were at either high or
unclear risk of bias. Participants were recruited over five decades
(1966 to 2017). For objective outcomes such as total mortality,
we had planned that trials we assessed as adequate with regard
to the domains of sequence generation, allocation concealment,
complete outcome data and absence of selective reporting would
be assessed as being at low risk of bias overall. None of the included
studies met all these criteria. None of the trials included in this
systematic review used, or reported using, blinding of either the
participants or outcome assessors. It is recognised that blinding is
difficult to maintain in trials of surgery and it may not be either
possible, or indeed ethical, to blind trial participants. It is likely
that many outcome assessments are performed by the clinicians
treating the participants.
There has been substantial developments in the surgical and non-
surgical treatments for both oral and oropharyngeal cancers over
recent years. Further objective assessments of current surgical treat-
ments for these cancers are needed to inform both patients and
clinicians about the benefits and risks of different treatments.
Potential biases in the review process
The search strategy was comprehensive with no language restric-
tions, and we clearly specified inclusion criteria for the review in
line with the other reviews in this series (Furness 2011; Glenny
2010), so the risk of biased selection of studies was minimal.
Figure 3 provides an indication of the review authors’ judgements
about each risk of bias item presented as percentages across all
included studies. The decision to look at blinding for overall sur-
vival (low risk of bias assessment), which is then used for all nine
outcomes, is a source of bias in the review process.
35Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment (Review)
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Agreements and disagreements with other
studies or reviews
We found two reviews of treatment of neck dissection in the sur-
gical treatment of oral cavity cancer based on the same included
studies (Fasunla 2011; Kowalski 2007). Kowalski 2007 looked
at dichotomous outcomes (percentages in each group) in three
RCTs. No meta-analysis was undertaken and only the summary
outcome estimates were noted, without regard to the variance of
these. Their conclusions were based on ”vote-counting.“
Fasunla 2011 reviewed four RCTs and reported the dichotomous
outcome of disease-specific death after approximately three years
of follow-up. This review found that the RR of disease-specific
death favoured elective neck dissection (RR 0.57, 95% CI 0.36 to
0.89).
We chose to use the outcome of overall survival/total mortality
becausewe believe this is themore important outcome for patients,
and we have used HRs where possible, as they have the advantage
of incorporating all available information, including data from
participants who failed to complete the trial, in the outcome. We
look forward to the addition of data from the three ongoing trials
identified to the next update of this review.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review includes 12 randomised controlled trials that evalu-
ated neck dissection surgery in participants with oral cavity can-
cers. We found insufficient evidence to draw conclusions about
elective neck dissection of clinically negative neck nodes at the
time of removal of the primary tumour compared to therapeu-
tic neck dissection. Two studies using radical neck dissection as
the elective procedure did not find a difference between interven-
tions, while one trial found that elective supraomohyoid neck dis-
section may be associated with increased overall and disease-free
survival when compared to a therapeutic neck dissection. Three
studies had inconclusive results for locoregional recurrence, and
one found this was reduced with elective neck dissection. There is
no evidence that elective radical neck dissection increases overall
survival compared to more conservative neck dissection surgery.
There is no evidence of a difference in mortality between PET-
CT surveillance following chemoradiotherapy versus plannedND
(before or after chemoradiotherapy). Reporting of adverse events
in all trials was poor and it was not possible to compare the qual-
ity of life of participants undergoing different surgeries. Available
evidence for all comparisons and outcomes is very low certainty
and results should be interpreted in light of this.
Implications for research
We would make the following recommendations for future re-
search involving the surgical treatment of oral or oropharyngeal
tumours.
• Trialists are encouraged to follow the CONSORT
guidelines when reporting on their trials. Ideally, trials should
report hazard ratios with 95% confidence intervals for survival
data, or present data that allows for the calculation of this
estimate of effect.
• Health-related quality of life is an important outcome
measure that should be integral to all trials of oral cavity and
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oropharyngeal cancers.
• There should be a standardised and consistent reporting of
adverse events and morbidity associated with treatment, with
results reported per participant.
• Future trials of oral cavity and oropharyngeal cancers
should report data based on the location of the primary tumour.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
BHNCSG 1998
Methods Location of trial: Brazil
Number of centres: multicentre (8)
Funding: not stated
Trial ID: not stated
Participants Inclusion criteria: resectable T2 to T4 lesions; clinically negative neck (N0); no prior
treatment; histological diagnosis of SCC of the oral tongue, FOM, inferior gingiva or
RMT; no need for myocutaneous or free flaps for reconstruction; Karnofsky score ≥ 60
Exclusion criteria: significant cardiac or pulmonary diseases, distant metastases or mul-
tiple primary cancers (or both)
Recruitment period: May 1990 to December 1993
Number randomised: 148 (all OC: 42% tongue, 33% FOM, 8% inferior gingiva, 17%
RMT)
Number analysed: 148
Interventions MRND vs SOH
Group 1 (n = 76): MRND: surgery conducted centripetally toward the submandibular
triangle
Group 2 (n = 72): SOH: dissection performed to achieve a compartmental excision
of levels I, II and III lymph nodes. Where a positive node was confirmed during the
procedure, the operation was converted to an MRND
For both groups, PORT was indicated in cases with positive margins or positive lymph
nodes (or both) in the specimen. RT was over 5 consecutive weeks to deliver a total dose
of 50 Gy
All participants had primary tumour resection.
Outcomes Primary: overall survival, recurrence
Secondary: adverse events
Duration of follow-up: 5 years
Notes HR data taken from Kaplan-Meier graph (no numbers at risk).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”Patients were stratified by institu-
tion and laterality (unilateral or bilateral)
and subsequently randomised.“
Method of sequence generation not de-
scribed.
Allocation concealment (selection bias) Unclear risk Insufficient information to determine ’yes’
or ’no.’
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BHNCSG 1998 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Mortality was primary outcome and con-
sidered an objective outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk Groups appeared similar at baseline.No ev-
idence of other potential sources of bias
Bier 1994
Methods Location of trial: Germany, Austria and Switzerland
Number of centres: multicentre
Funding: not stated
Trial ID: not stated (part of The German-Austrian-Swiss Association for Head and Neck
Tumours (DOSAK))
Participants Inclusion criteria: untreated SCC of the oral cavity without metastases, primary tumour
on 1 side postcanine or postmolar, i.e. second (postcanine) or third (postmolar) part
of the tongue, non-palpable or clinically negative, or clinically positive, movable lymph
nodes in the neck
Exclusion criteria: fixed lymph nodes in the neck.
Recruitment period: uncertain
Number randomised: 167 (all OC: 37% tongue, 21%FOM, 16%RMT, 14%mandible,
8% maxilla, 3% cheek, 1% other)
Number analysed: 104
Interventions Radical ND vs selective ND
Group 1 (n = 48): radical ND (ipsilateral) on the draining lymph nodes. Radical dis-
section designated as removal of: 1. platysma, sternocleidomastoid muscle, omohyoid
muscle, stylohyoid muscle, distal part of the biventer cervicis and fascia colli; 2. the ac-
cessory nerve, descending branch of the hypoglossus nerve and branches of the cervical
plexus; 3. the cervical vein, superficial jugular vein and internal jugular vein; 4. fat tissue,
submandibular gland and lower part of the parotid gland
Group 2 (n = 56): selective ND (ipsilateral) on the draining lymph nodes. Selective
dissection designated as retention of the platysma, sternocleidomastoid muscle, internal
jugular vein and the accessory nerve
All participants underwent radical resection of the primary tumour
Outcomes Primary: overall survival, recurrence
Secondary: metastases
Duration of follow-up: 4 years
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Bier 1994 (Continued)
Notes Preliminary report
ND was followed by RT or chemotherapy (or both) in participants not undergoing
radical resection of the primary tumour and in participants with capsular rupture in ≥
1 lymph node. These participants were not included in the analysis
HR data taken from Kaplan-Meier graph (no numbers at risk).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”Randomized according to
the treatment-dependant prognostic index
(TPI) of the DOSAK.“
Method of sequence generation not de-
scribed.
Allocation concealment (selection bias) Unclear risk Insufficient information to determine ’yes’
or ’no.’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Mortality was primary outcome and con-
sidered an objective outcome
Incomplete outcome data (attrition bias)
All outcomes
High risk Interim analysis of 104/167 participants
randomised published in 1994. No subse-
quent publication identified. Participants
who did not have radical surgery at the pri-
mary site and participants who had extra-
capsular rupture of ≥ 1 lymph node were
not included in the evaluation
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Unclear risk No information about comparability of
groups at baseline.
D’Cruz 2015
Methods Location of trial: India
Number of centres: 1
Funding: Tata Memorial Centre
Trial ID: NCT00193765
Participants Inclusion criteria: aged 18-75 years with histopathologically confirmed, invasive SCC
of the oral cavity (tongue, FOM or buccal mucosa) that met the staging criteria of the
Union for International Cancer Control tumour stage T1 (measuring ≤ 2 cm) or T2
(measuring > 2 cm but < 4 cm) that was lateralised to 1 side of the midline. In addition,
all participants had received no previous treatment, were amenable to undergoing oral
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D’Cruz 2015 (Continued)
excision, and had no history of head and neck cancer
Exclusion criteria: previous surgery in the head and neck region, upper alveolar or palatal
lesions, large heterogeneous leukoplakias or diffuse oral submucous fibrosis
Recruitment period: 2004-2014
Number randomised: 596
Number analysed: 496
Interventions Elective vs therapeutic ND in node-negative OC
Group 1 (n = 298): underwent elective surgery (ipsilateral selective ND with clearance
of the submandibular (level I), upper jugular (level II), and midjugular (level III) nodes).
Participants with metastatic nodal disease that was discovered during surgery (operative
findings or frozen section), had amodifiedNDperformedwith nodal clearance extended
to include the lower jugular (level IV) and posterior triangle (level V) nodes
Group 2 (n = 298): underwent therapeutic surgery (the same surgical procedure for the
primary tumour and were then monitored, with modified ND (levels I-V) only at the
time of nodal relapse
All participants underwent oral excision of the primary tumour with adequate margins
(i.e. ≥ 5 mm)
All participants underwent secondary randomisation for follow-up (to receive either
physical examination or physical examination + ultrasonography of the neck)
Outcomes Primary: overall survival, DFS, nodal relapse, regional recurrence
Secondary: none noted
Duration of follow-up: median 39 months
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Used a computer random number gener-
ator (i.e. prepared computerised block de-
sign)
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment of ’low risk’ or ’high risk.’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Survival was primary outcome and consid-
ered an objective outcome
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 45 participants excluded from elective
surgery group (1 withdrew consent, 1 had
previous chemotherapy, 43 did not com-
plete 9-month follow-up)
55 participants excluded from therapeutic
surgery group ( 2 had lesion crossing mid-
line, 53 did not complete 9-month follow-
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D’Cruz 2015 (Continued)
up
Selective reporting (reporting bias) Low risk Study protocol available and all of the
study’s prespecified (primary and sec-
ondary) outcomes that were of interest in
the review were reported as per the proto-
col
Other bias Low risk No other apparent bias
Fakih 1989
Methods Location of trial: India
Number of centres: 1
Funding: not stated
Trial ID: not stated
Participants Inclusion criteria: T1 to T2, N0 M0, histologically confirmed SCC of the anterior two-
thirds of the oral tongue
Exclusion criteria: not stated
Recruitment period: July 1985 to September 1988
Number randomised: 100 (all OC; 100% tongue)
Number analysed: 70
Interventions Elective radical ND vs therapeutic radical ND
Group 1 (n = 30): radical ND (ipsilateral)
Group 2 (n = 40): only participants developing neck node metastasis underwent radical
ND
All participants underwent resection of the primary tumour (standard anterior two-
thirds hemiglossectomy)
Outcomes Primary: overall survival, DFS, disease-related mortality, recurrent disease
Secondary: none noted.
Duration of follow-up: 1 year
Notes No data available for calculation of HR
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”Randomised from previously gen-
erated random numbers.“
Allocation concealment (selection bias) Unclear risk Insufficient information to determine ’yes’
or ’no.’
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Fakih 1989 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Survival was primary outcome and consid-
ered an objective outcome
Incomplete outcome data (attrition bias)
All outcomes
High risk Interim analysis, no final analysis reported.
73 participants entered into protocol, 12
refused treatment and 2 were declared unfit
for surgery. Of the remaining 59 who com-
pleted initial treatment, 35 who completed
a median of 22 months follow-up were in-
cluded in the analysis (approximately 48%)
Selective reporting (reporting bias) Low risk No evidence of selective outcome report-
ing.
Other bias Unclear risk No information about comparability of
groups at baseline.
Guo 2014
Methods Location of trial: China
Number of centres: 1
Funding: not stated
Trial ID: not stated
Participants Inclusion criteria: tumour located in the tongue, gingiva, buccal area, FOM, oropharynx
or hard palate; no evidence of distant metastasis; no previous treatment
Exclusion criteria: not stated
Recruitment period: June 1999 to May 2010
Number randomised: 332
Number analysed: 322
Interventions SOH ND vs modified radical ND for clinically node-negative oral SCC
Group 1 (n = 166): allocated to SOHND arm (received surgery alone (n = 109), received
surgery + PORT (n = 57))
Group 2 (n = 166): allocated to MRND arm (received surgery alone (n = 114), received
surgery + PORT (n = 52))
Outcomes Primary: DSS, NCR
Secondary: quality of life (QoL) assessments
Duration of follow-up: median 76 months (1 year for QoL)
Notes NCR defined as proportion of participants who did not develop postoperative nodal
metastases within 3 years
Risk of bias
Bias Authors’ judgement Support for judgement
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Guo 2014 (Continued)
Random sequence generation (selection
bias)
Unclear risk Insufficient information about the se-
quence generation process to permit judge-
ment of ’low risk’ or ’high risk.’
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment of ’low risk’ or ’high risk.’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Mortality was primary outcome and con-
sidered an objective outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk 10 (3%) participants lost to follow-up soon
after randomisation were unable to be in-
cluded in the analysis (4 in SOHND treat-
ment arm, 6 in MRND treatment arm)
Selective reporting (reporting bias) Low risk No evidence of selective outcome report-
ing.
Other bias Low risk No other apparent bias.
Iyer 2015
Methods Location of trial: Singapore
Number of centres: not stated
Funding: not stated
Trial ID: not stated
Participants Inclusion criteria: people newly diagnosedwith histologically confirmed, resectable, non-
metastatic stage III/IV HNSCC who had a good Eastern Cooperative Oncology Group
performance status (0 or 1) and adequate bone marrow, hepatic and renal function
Exclusion criteria: nasopharynx and salivary glands
Recruitment period: August 1996 to February 2002
Number randomised: 119
Number analysed: 118
Interventions Surgery and adjuvant RT vs concurrent CRT
Group 1 (n = 60): radical surgery + adjuvant RT
Group 2 (n = 59): combination chemotherapy with cisplatin and 5-fluorouracil and
concurrent RT
Randomisation was stratified according to primary tumour site (oral cavity/oropharynx,
larynx/hypopharynx, others) and lymph node status (lymph-node positive vs lymph-
node negative)
Outcomes To determine whether concurrent chemotherapy was superior to the prevailing con-
ventional treatment at that time, namely surgery and adjuvant RT, with survival as the
endpoint
Primary: overall survival, DSS, locoregional recurrence-free survival, distant recurrence-
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Iyer 2015 (Continued)
free survival
Secondary: none noted
Duration of follow-up for all participants: 10 years
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of sequence generation not de-
scribed.
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Survival was primary outcome and consid-
ered an objective outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 1 participant missing from analysis
as histopathological assessment confirmed
adenocarcinoma, therefore excluded
Selective reporting (reporting bias) Low risk No evidence of selective outcome report-
ing.
Other bias Low risk No other apparent bias.
Kligerman 1994
Methods Location of trial: Brazil
Number of centres: 1
Funding: government (personal communication)
Trial ID: not stated
Participants Inclusion criteria: resectable early stage (T1 to T2, N0) SCC of tongue and FOM
Exclusion criteria: not stated
Recruitment period: 1987-1992
Number randomised: 67 (all OC: 61% tongue, 39% FOM)
Number analysed: 67
Interventions Elective ND vs therapeutic ND
Group1 (n=34): elective SOHND.Dissectionof levels 1-3 + resectionof submandibular
gland, preserving the sternocleidomastoid muscle, spinal accessory nerve and internal
jugular vein
Group 2 (n = 33): therapeutic ND
All participants underwent resection of the primary tumour.
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Kligerman 1994 (Continued)
Outcomes Primary: overall survival, DFS, locoregional recurrence, disease-related mortality
Secondary: none noted
Duration of follow-up: 3.5 years
Notes Paper reported that overall survival assessed by Kaplan-Meier actuarial method, but not
presented
HR data taken from Kaplan-Meier graph (no numbers at risk) for DFS
Locoregional failure data unclear.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”All 67 patients were stratified by
stage...and those in each stage were ran-
domised.“
Method of sequence generation not de-
scribed.
Allocation concealment (selection bias) Unclear risk Insufficient information to determine ’yes’
or ’no.’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Mortality was primary outcome and con-
sidered an objective outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts
Selective reporting (reporting bias) Low risk No evidence of selective outcome reporting
Other bias Unclear risk No information about comparability of
groups at baseline
Mehanna 2017
Methods Location of trial: UK
Number of centres: 38
Funding:Health Technology programme ofNational Institute forHealth ResearchTech-
nology Assessment Programme and Cancer Research UK
Trial ID: ISRCTN13735240
Participants Inclusion criteria (must have met all):
• histological diagnosis of oropharyngeal, laryngeal, oral, hypopharyngeal or occult
HNSCC;
• clinical and CT/MRI imaging evidence of nodal metastases staged N2 (a, b or c)
or N3;
• indication to receive curative radical concurrent CRT for primary;
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Mehanna 2017 (Continued)
• fitness for ND surgery;
• ND was technically feasible to perform and remove nodal disease (e.g. no carotid
encasement, no direct extension between tumour and nodal disease);
• aged ≥ 18 years;
• able to give informed consent;
• receiving 1 of the CRT regimens approved by the study.
Exclusion criteria (any criteria met ruled patients ineligible):
• undergoing resection for primary tumour (diagnostic tonsillectomy was not
considered an exclusion criteria);
• distant metastases to chest, liver, bones or other sites;
• previous treatment for HNSCC;
• pregnant;
• another cancer diagnosis in the past 5 years (except basal cell carcinoma or
carcinoma of the cervix in situ).
Recruitment period: 2 October 2007 to 23 August 2012
Number randomised: 564 (84.4% OP cancer)
Number analysed: 564 (personal communication)
Interventions PET-CT surveillance (following CRT) vs planned ND (either before or after CRT)
in advanced head and neck cancer
Assessed the non-inferiority of PET-CT-guided surveillance (performed 12 weeks after
the end of CRT, withNDperformed only if PET-CT showed an incomplete or equivocal
response) to planned ND (either before or after CRT) in people with stage N2 or N3
disease
Group 1 (n = 282): PET-CT 12 weeks after completion of CRT (surveillance group)
Group 2 (n = 282): planned ND (either before or after CRT)
Outcomes Primary: overall survival
Secondary: quality of life, surgical complications
Follow-up period: 36 months (median)
Notes Before randomisation, each participating centre had to specify on a per-participant basis
whether planned ND would be performed within 4 weeks before or within 4-8 weeks
after completion of CRT. In addition, before randomisation, clinicians selected CRT
regimens from a list of the approved study regimens
Intention-to-treat analysis was carried out for all 564 participants. Kaplan-Meier analysis
was used to estimate survival rate due to the loss of some participants
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Minimisation algorithm used; table 1 listed
variables for comparison
Allocation concealment (selection bias) Unclear risk Unclear how allocation concealment oc-
curred.
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Mehanna 2017 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Survival was primary outcome and consid-
ered an objective outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants assessed as part of the in-
tention-to-treat analysis
Selective reporting (reporting bias) Low risk Study protocol was published and out-
comes were published according to proto-
col
Other bias Low risk No other potential sources of bias identi-
fied.
Rastogi 2018
Methods Location of trial: India
Number of centres: 1
Funding: not stated
Trial ID: not stated
Participants Inclusion criteria: aged > 18 years, established diagnosis of SCC as defined by the AJCC
classification, T1-T3 lesions of the oral cavity with N0 neck
Exclusion criteria: requiring radical NDormodified radical ND; history of surgery or RT
of the head and neck region; history of shoulder pain, dysfunction or weakness including
myopathy, neuropathy or arthropathy; any type of implanted electrical device prior
to surgery; previous or current neurological illness; did not provide written informed
consent; unwilling to attend follow-up appointments
Recruitment period: August 2014 to March 2017
Number randomised: 20
Number analysed: 20
Interventions Selective ND vs super-selective ND for people with oral carcinoma and N0 neck in
terms of shoulder morbidity and recurrence rate
Group 1 (n = 10): selective ND of levels I, IIa, IIb and III
Group 2 (n = 10): super selective ND of levels I, IIa and III
Outcomes Primary: rate of recurrence over 2.5 years
Secondary: ArmAbductionTest, quality of life assessed by subjective questionnaire (Neck
Dissection Quality of Life Questionnaire)
Duration of follow-up period for all participants: 2.5 years
Notes Small sample size
Risk of bias
Bias Authors’ judgement Support for judgement
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Rastogi 2018 (Continued)
Random sequence generation (selection
bias)
Unclear risk Unclear how the randomisation occurred
using the ”slot method.“
Allocation concealment (selection bias) Unclear risk Unclear if the investigators utilised appro-
priate allocation concealment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Mortality was primary outcome and con-
sidered an objective outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the trial with
analysis undertaken for all
Selective reporting (reporting bias) Low risk Outcomes clearly stated inmethods section
and appropriately measured in results sec-
tion
Other bias Low risk No other sources of bias noted.
Robertson 1998
Methods Location of trial: UK
Number of centres: multicentre (4)
Funding: not stated
Trial ID: not stated
Participants Inclusion criteria: resectable, stage T2-T4, N0-N2, M0 head and neck tumours
Exclusion criteria: stage I (T1N0M0); history of malignancy, apart from basal cell car-
cinoma of the skin, or intraepithelial carcinoma of the cervix
Recruitment period: December 1991 to December 1993
Number randomised: 35 (intended 350 but trial stopped early due to concern of the
number of deaths in the RT alone arm) (33/35 OC: 40% tongue, 43% FOM, 11%
RMT, 6% tonsil)
Number analysed: 35
Interventions Surgery + RT vs RT alone
Group 1 (n = 17): radical resection and ND + PORT. Radical surgery involved wide
local excision of the primary tumour with 1 cm margin. A radical or functional ND
was carried out at the same time at the discretion of the surgeon. Reconstruction of the
oral cavity was carried out immediately. PORT comprised 60 Gy in 30 fractions over 6
weeks, commencing within 6-8 weeks of surgery
Group 2 (n = 18): RT alone; 66 Gy in 33 fractions over 6.5 weeks, receiving 2 Gy per
day
Outcomes Primary: overall survival, disease-free interval, recurrent disease, locoregional control
Secondary: adverse events
Duration of follow-up: 3 years
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Robertson 1998 (Continued)
Notes HR data taken from Kaplan-Meier graph (no numbers at risk).
Data presented in Kaplan-Meier estimates for DFS, but not used as graph started at 50%
for RT alone arm.
Authors provided additional information relating to allocation concealment and the
characteristics of tumours
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”Random permuted blocks of four
were used for randomization“ following
stratification according to institution and
site of primary disease
Allocation concealment (selection bias) Low risk Randomisation via a telephone call to the
West of Scotland Clinical Trials Office
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Mortality was primary outcome and con-
sidered an objective outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts
Selective reporting (reporting bias) Low risk No evidence of selective reporting of out-
comes.
Other bias High risk Anticipated enrolment of 350 participants,
but trial stopped after 35 participants re-
cruited because clinicians felt it was uneth-
ical to continue. Appropriate procedures
and analysis were conducted. More than
half of participants recruited had either de-
lays or interruptions to the planned RT
schedule. It is likely that this would have
had a greater effect on the outcomes of the
RT alone arm of this trial
Vandenbrouck 1980
Methods Location of trial: France
Number of centres: 1
Funding: not stated
Trial ID: not stated
Participants Inclusion criteria: T1-T3, N0, SCC oral cavity, tongue or lower FOM; any age or sex
with no previous transcutaneous RT or interatrial chemo infusion; neck free of disease
or with moveable submaxillary node/s no larger than 1 cm
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Vandenbrouck 1980 (Continued)
Exclusion criteria: not stated
Recruitment period: 1966-1973
Numbers randomised: 80 (all OC; 56% tongue, 44% FOM)
Numbers analysed: 75
Interventions Elective radical ND vs therapeutic radical ND
Group 1 (n = 39): elective ND within 2 months of treatment of primary lesion. In
cases of lateral tumour, an ipsilateral radical ND with removal of sternocleidomastoid
muscle, internal jugular vein without sparing the spinal accessory nerve was performed.
When tumour crossed or close to midline submental, submaxillary and jugulodigastric
contralateral dissection performed. Nodal involvement resulted in PORT
Group 2 (n = 36): therapeutic (delayed) dissection. These participants were followed for
≥ 3 years and underwent ND if a cervical node became enlarged
All participants received interstitial RT to the primary tumour site prior to randomisation
Outcomes Primary: overall survival, DFS, disease-related mortality, recurrent disease
Secondary: none noted
Duration of follow-up period: 5 years
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”Randomisation was under the
control of a statistician who observed the
strictest protocol.“
However, method of sequence generation
was not described.
Allocation concealment (selection bias) Low risk Quote: ”Randomisation was under the
control of a statistician who observed the
strictest protocol.“
Assumed this was adequate.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Survival was primary outcome and consid-
ered an objective outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts
Selective reporting (reporting bias) Low risk No evidence of selective outcome report-
ing.
Other bias Low risk No evidence of other potential sources of
bias.
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Yuen 2009
Methods Location of trial: Hong Kong, China
Number of centres: 3
Funding: not stated
Trial ID: not stated
Participants Inclusion criteria: AJCC, Stage I to II, SCC oral tongue; no nodal metastases; no prior
surgery, chemotherapy or RT
Exclusion criteria: OC of other subsites, or cancer of base of tongue
Recruitment period: 1996-2004
Numbers randomised: 72 (all OC: 100% tongue)
Numbers analysed: 71
Interventions Elective selective ND vs therapeutic radical ND
Group 1 (n = 36): elective ipsilateral selective ND of level I, II or III neck nodes
Group 2 (n = 36): therapeutic (delayed) dissection. These participants were followed,
and received ultrasound examinations every 3 months for the first 3 years. If nodal
recurrence was detected, these participants underwent either radical or modified radical
ND followed by RT
All participants in the trial had transoral glossectomy with 1.5 resection margins
Outcomes Primary: nodal recurrence, disease recurrence, death due to tumour, 5-year tumour-
specific survival
Duration of follow-up: 34-122 months
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation stratified by tumour stage.
Method of sequence generation not de-
scribed
Allocation concealment (selection bias) Unclear risk Used sealed envelopes to contain the alloca-
tion. Insufficient information to determine
whether allocation was concealed from in-
vestigators
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Mortality was primary outcome and con-
sidered an objective outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 participant allocated to observation
group was subsequently found to have T3
tumour and was withdrawn. All other ran-
domised participants included in the out-
come evaluations
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Yuen 2009 (Continued)
Selective reporting (reporting bias) High risk Reported nodal and local recurrence, DFS
and disease-specific death. No reporting of
mortality in each group
Other bias Low risk Groups appeared similar at baseline.
AJCC: American Joint Committee on Cancer; CRT: chemoradiotherapy; CT: computer tomography; DFS: disease-free survival; DSS:
disease-specific survival; FOM: floor of mouth; HNSCC: head and neck squamous-cell carcinoma; HR: hazard ratio; MRI: magnetic
resonance imaging; MRND: modified radical classical neck dissection; n: number of participants; NCR: neck control rate; ND: neck
dissection; OC: oral cancer; OP: oropharyngeal cancer; PET-CT: positron-emission tomography-computed tomography; PORT:
postoperative radiotherapy; RMT: retromolar trigone; RT: radiotherapy; SCC: squamous-cell carcinoma; SE: standard error; SOH:
supraomohyoid neck dissection.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abbade 2015 Study was about basal cell carcinoma, which is not related to oral cavity cancer
Ajmani 2017 Not an RCT
Ang 2001 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: radiother-
apy’ (Glenny 2010).
Batra 2016 Short-term outcomes only (wound closure).
Bernier 2004 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: chemo-
therapy’ (Furness 2011).
Bier 1981 RCT to be included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: im-
munotherapy.’
Cooper 2004 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: chemo-
therapy’ (Furness 2011).
De Stefani 2002 RCT to be included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: im-
munotherapy.’
Dean 2013 Short-term outcomes only (e.g. operative time, reduces blood loss during surgery, time drains are kept in place,
amount of drainage)
Fan 2017 Short-term outcomes only (e.g. postoperative immune response and surgical stress)
60Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Fritz 2016 Short-term outcomes only (e.g. blood loss and operating time)
Funahara 2017 Short-term outcomes only (e.g. surgical wound infections).
George 2014 Not an RCT
Gundale 2017 Abstract, insufficient information
Hintz 1979a Head and neck cancer study with < 50% oral cancer/oropharyngeal cancer
Hintz 1979b Head and neck cancer study with < 50% oral cancer/oropharyngeal cancer
Howard 2016 Systematic review
Jinyun 2015 Not an RCT
Kramer 1987 Insufficient detail in published report to establish what the surgical procedures involved and whether these were
the same in all groups. Insufficient information to enable either risk of bias assessment to be undertaken
Lam 2001 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: chemo-
therapy’ (Furness 2011).
Laramore 1992 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: chemo-
therapy’ (Furness 2011).
Lawrence 1974 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: radiother-
apy’ (Glenny 2010).
Licitra 2001 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: chemo-
therapy’ (Furness 2011).
Lin 2016 Short-term study only looking at immediate postsurgical outcomes
Luboinski 1985 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: chemo-
therapy’ (Furness 2011).
Maipang 1995 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: chemo-
therapy’ (Furness 2011).
McCaul 2012 Abstract, insufficient information
McCaul 2017 Abstract, insufficient information
Minkovich 2011 Short-term outcomes only (e.g. malpositions of peripherally inserted central venous catheters)
Mohr 1994 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: chemo-
therapy’ (Furness 2011).
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(Continued)
Neifeld 1985 RCT to be included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: im-
munotherapy.’
Oswal 2017 Short-term outcomes only (e.g. wound closure).
Paccagnella 1994 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: chemo-
therapy’ (Furness 2011).
Poh 2011 6 months post-treatment; short-term follow-up only.
Rao 1991 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: chemo-
therapy’ (Furness 2011).
Rentschler 1987 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: chemo-
therapy’ (Furness 2011).
Richard 1991 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: chemo-
therapy’ (Furness 2011).
Sanguineti 2005 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: radiother-
apy.’
Schuller 1988 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: chemo-
therapy’ (Furness 2011).
Szabo 1999 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: chemo-
therapy’ (Furness 2011).
Szpirglas 1978 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: chemo-
therapy’ (Furness 2011).
Terz 1981 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: radiother-
apy.’
Tingting 2016 Not different surgical term
Uppal 2012 Unable to access the original article.
Verma 2017 Short-term study only looking at immediate postsurgical outcomes
Volling 1999 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: chemo-
therapy’ (Furness 2011).
Walen 2011 Short-term study on postoperative pain.
Weissler 1992 RCT now included in review ’Interventions for the treatment of oral cavity and oropharyngeal cancer: chemo-
therapy’ (Furness 2011).
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(Continued)
Zhang 2010 Abstract, insufficient information
Zhong 2013 Surgery was not the comparison, mainly chemotherapy.
Zhong 2015 Surgery was not the comparison, mainly chemotherapy
RCT: randomised controlled trial.
Characteristics of ongoing studies [ordered by study ID]
NCT00571883 (SEND)
Trial name or title Neck surgery in treating patients with early-stage oral cancer (SEND trial)
Methods RCT
Participants People with oral squamous-cell carcinoma 1-3 cm at primary site, no clinical or preoperative imaging evidence
of neck involvement (N0)
Interventions Selective elective neck dissection + resection of primary tumour vs resection of primary alone
Outcomes Overall survival, disease-free survival, local and regional recurrence, completeness of primary resection, QoL,
psychological wellbeing, costs
Starting date January 2007
Contact information Study chair: Iain Hutchison, Facial Surgery Research Foundation, UK (send@savingfaces.info)
Notes Currently recruiting July 2009
NCT01334320
Trial name or title Survival benefit of elective neck dissection in T1, 2 N0 M0 oral squamous cell carcinoma
Methods RCT
Participants Histologically confirmed T1 or T2 N0M0 (clinical) squamous-cell carcinoma of oral tongue, buccal mucosa,
gingiva, floor of mouth or hard palate
Interventions Elective superior omohyoid neck dissection vs watch and wait (resection of primary tumour and therapeutic
dissection of neck when clinical evidence of disease)
Outcomes Overall and disease-free survival at 5 years, recurrence, QoL
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NCT01334320 (Continued)
Starting date April 2011
Contact information Dr Guiqing Lao, Hospital of Stomatology, Sun Yat-sen University, Guangdong, China (drliaogu-
iqing@hotmail.com)
Notes Planned enrolment 448 participants
Nichols 2013 (formerly NCT01590355)
Trial name or title Early-stage squamous cell carcinoma of the Oropharynx: Radiotherapy vs. Trans-Oral Robotic Surgery (OR-
ATOR) - study protocol for a randomized phase II trial
Methods RCT. Phase II
Participants People with oropharyngeal squamous-cell carcinoma who would be unlikely to require chemotherapy postre-
section, people with N0 disease will receive radiotherapy alone, whereas people with N1-2 disease will receive
concurrent chemoradiotherapy
Interventions Participants will undergo transoral robotic surgery along with selective neck dissections, which may be staged
Outcomes Primary endpoint QoL score usingM.D. AndersonDysphagia Inventory, with secondary endpoints including
survival, toxicity, other QoL outcomes and swallowing function
Starting date 2013
Contact information david.palma@lhsc.on.ca
Department of Otolaryngology-Head and Neck Surgery, London Health Sciences Centre and Western Uni-
versity, London, ON, Canada
Notes Sample of 68 participants is required.
QoL: quality of life; RCT: randomised controlled trial.
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D A T A A N D A N A L Y S E S
Comparison 1. Elective neck dissection (ND) versus therapeutic (delayed) neck dissection
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total mortality (HR for overall
survival)
2 Hazard Ratio (Random, 95% CI) Subtotals only
1.1 Elective radical neck
dissection vs therapeutic radical
neck
2 Hazard Ratio (Random, 95% CI) 0.84 [0.41, 1.72]
2 Total mortality 2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Elective radical neck
dissection vs therapeutic neck
dissection (1 year)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Elective supraomohyoid
neck dissection (SOH) neck
dissection vs therapeutic neck
dissection (3.5 years)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 New disease, progression or
mortality (HR for disease-free
survival)
3 Hazard Ratio (Random, 95% CI) Subtotals only
3.1 Elective radical neck
dissection vs therapeutic radical
neck
2 Hazard Ratio (Random, 95% CI) 0.73 [0.25, 2.11]
3.2 Elective SOH neck
dissection vs therapeutic neck
dissection (3.5 years)
1 Hazard Ratio (Random, 95% CI) 0.32 [0.12, 0.84]
4 New disease, progression or
mortality
2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 Elective radical neck
dissection vs therapeutic neck
dissection (1 year)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Elective radical neck
dissection vs therapeutic radical
neck dissection (3 years)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Locoregional recurrence 4 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5.1 Elective radical neck
dissection vs therapeutic neck
dissection (1 year)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Elective SOH neck
dissection vs therapeutic neck
dissection (3.5 years)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.3 Elective selective neck
dissection vs therapeutic neck
dissection
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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5.4 Elective radical neck
dissection vs therapeutic radical
neck dissection (3 years)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. Radical neck dissection (ND) versus selective neck dissection
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total mortality (HR for overall
survival)
2 Hazard Ratio (Fixed, 95% CI) Totals not selected
1.1 Modified radical classical
neck dissection (MRND) vs
supraomohyoid neck dissection
(SOH)
1 Hazard Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Radical neck dissection vs
selective neck dissection
1 Hazard Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
2 New disease, progression or
mortality (HR for disease-free
survival)
1 Hazard Ratio (Fixed, 95% CI) Totals not selected
2.1 Radical neck dissection vs
selective neck dissection
1 Hazard Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Recurrence 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Resection + elective
supraomohyoid dissection vs
resection alone (5 years)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 3. Surgery plus radiotherapy (RT) versus radiotherapy alone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total mortality (HR for overall
survival)
1 Hazard Ratio (Fixed, 95% CI) Totals not selected
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Comparison 4. Positron-emission tomography-computed tomography (PET-CT) versus planned neck dissection
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total mortality (HR for overall
survival)
1 Hazard Ratio (Random, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Elective neck dissection (ND) versus therapeutic (delayed) neck dissection,
Outcome 1 Total mortality (HR for overall survival).
Review: Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment
Comparison: 1 Elective neck dissection (ND) versus therapeutic (delayed) neck dissection
Outcome: 1 Total mortality (HR for overall survival)
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Elective radical neck dissection vs therapeutic radical neck
D’Cruz 2015 -0.45 (0.18) 62.8 % 0.64 [ 0.45, 0.91 ]
Vandenbrouck 1980 0.3 (0.42) 37.2 % 1.35 [ 0.59, 3.07 ]
Subtotal (95% CI) 100.0 % 0.84 [ 0.41, 1.72 ]
Heterogeneity: Tau2 = 0.18; Chi2 = 2.69, df = 1 (P = 0.10); I2 =63%
Test for overall effect: Z = 0.47 (P = 0.64)
0.05 0.2 1 5 20
Favours elective ND Favours therapeutic ND
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Analysis 1.2. Comparison 1 Elective neck dissection (ND) versus therapeutic (delayed) neck dissection,
Outcome 2 Total mortality.
Review: Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment
Comparison: 1 Elective neck dissection (ND) versus therapeutic (delayed) neck dissection
Outcome: 2 Total mortality
Study or subgroup Elective ND Therapeutic ND Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Elective radical neck dissection vs therapeutic neck dissection (1 year)
Fakih 1989 9/28 16/37 0.74 [ 0.39, 1.43 ]
2 Elective supraomohyoid neck dissection (SOH) neck dissection vs therapeutic neck dissection (3.5 years)
Kligerman 1994 7/34 17/33 0.40 [ 0.19, 0.84 ]
0.1 0.2 0.5 1 2 5 10
Favours elective ND Favours therapeutic ND
Analysis 1.3. Comparison 1 Elective neck dissection (ND) versus therapeutic (delayed) neck dissection,
Outcome 3 New disease, progression or mortality (HR for disease-free survival).
Review: Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment
Comparison: 1 Elective neck dissection (ND) versus therapeutic (delayed) neck dissection
Outcome: 3 New disease, progression or mortality (HR for disease-free survival)
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Elective radical neck dissection vs therapeutic radical neck
D’Cruz 2015 -0.8 (0.14) 56.5 % 0.45 [ 0.34, 0.59 ]
Vandenbrouck 1980 0.3 (0.42) 43.5 % 1.35 [ 0.59, 3.07 ]
Subtotal (95% CI) 100.0 % 0.73 [ 0.25, 2.11 ]
Heterogeneity: Tau2 = 0.51; Chi2 = 6.17, df = 1 (P = 0.01); I2 =84%
Test for overall effect: Z = 0.59 (P = 0.56)
2 Elective SOH neck dissection vs therapeutic neck dissection (3.5 years)
Kligerman 1994 -1.15 (0.5) 100.0 % 0.32 [ 0.12, 0.84 ]
Subtotal (95% CI) 100.0 % 0.32 [ 0.12, 0.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.30 (P = 0.021)
0.05 0.2 1 5 20
Favours elective ND Favours therapeutic ND
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Analysis 1.4. Comparison 1 Elective neck dissection (ND) versus therapeutic (delayed) neck dissection,
Outcome 4 New disease, progression or mortality.
Review: Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment
Comparison: 1 Elective neck dissection (ND) versus therapeutic (delayed) neck dissection
Outcome: 4 New disease, progression or mortality
Study or subgroup Elective ND Therapeutic ND Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Elective radical neck dissection vs therapeutic neck dissection (1 year)
Fakih 1989 19/28 21/37 1.20 [ 0.82, 1.75 ]
2 Elective radical neck dissection vs therapeutic radical neck dissection (3 years)
Vandenbrouck 1980 18/39 21/36 0.79 [ 0.51, 1.23 ]
0.1 0.2 0.5 1 2 5 10
Favours elective ND Favours therapeutic ND
69Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.5. Comparison 1 Elective neck dissection (ND) versus therapeutic (delayed) neck dissection,
Outcome 5 Locoregional recurrence.
Review: Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment
Comparison: 1 Elective neck dissection (ND) versus therapeutic (delayed) neck dissection
Outcome: 5 Locoregional recurrence
Study or subgroup Elective ND Therapeutic ND Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Elective radical neck dissection vs therapeutic neck dissection (1 year)
Fakih 1989 11/28 23/37 0.63 [ 0.37, 1.07 ]
2 Elective SOH neck dissection vs therapeutic neck dissection (3.5 years)
Kligerman 1994 8/34 14/33 0.55 [ 0.27, 1.14 ]
3 Elective selective neck dissection vs therapeutic neck dissection
Yuen 2009 6/36 14/35 0.42 [ 0.18, 0.96 ]
4 Elective radical neck dissection vs therapeutic radical neck dissection (3 years)
Vandenbrouck 1980 6/39 8/36 0.69 [ 0.27, 1.80 ]
0.1 0.2 0.5 1 2 5 10
Favours elective ND Favours therapeutic ND
Analysis 2.1. Comparison 2 Radical neck dissection (ND) versus selective neck dissection, Outcome 1 Total
mortality (HR for overall survival).
Review: Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment
Comparison: 2 Radical neck dissection (ND) versus selective neck dissection
Outcome: 1 Total mortality (HR for overall survival)
Study or subgroup log [Hazard Ratio] Hazard Ratio Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Modified radical classical neck dissection (MRND) vs supraomohyoid neck dissection (SOH)
BHNCSG 1998 0.13 (0.25) 1.14 [ 0.70, 1.86 ]
2 Radical neck dissection vs selective neck dissection
Bier 1994 -0.14 (0.38) 0.87 [ 0.41, 1.83 ]
0.01 0.1 1 10 100
Favours radical ND Favours selective ND
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Analysis 2.2. Comparison 2 Radical neck dissection (ND) versus selective neck dissection, Outcome 2 New
disease, progression or mortality (HR for disease-free survival).
Review: Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment
Comparison: 2 Radical neck dissection (ND) versus selective neck dissection
Outcome: 2 New disease, progression or mortality (HR for disease-free survival)
Study or subgroup log [Hazard Ratio] Hazard Ratio Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Radical neck dissection vs selective neck dissection
Bier 1994 -0.56 (0.34) 0.57 [ 0.29, 1.11 ]
0.01 0.1 1 10 100
Favours radical ND Favours selective ND
Analysis 2.3. Comparison 2 Radical neck dissection (ND) versus selective neck dissection, Outcome 3
Recurrence.
Review: Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment
Comparison: 2 Radical neck dissection (ND) versus selective neck dissection
Outcome: 3 Recurrence
Study or subgroup Radical ND Selective ND Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Resection + elective supraomohyoid dissection vs resection alone (5 years)
BHNCSG 1998 16/72 13/71 1.21 [ 0.63, 2.33 ]
0.1 0.2 0.5 1 2 5 10
Favours radical ND Favours selective ND
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Analysis 3.1. Comparison 3 Surgery plus radiotherapy (RT) versus radiotherapy alone, Outcome 1 Total
mortality (HR for overall survival).
Review: Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment
Comparison: 3 Surgery plus radiotherapy (RT) versus radiotherapy alone
Outcome: 1 Total mortality (HR for overall survival)
Study or subgroup log [Hazard Ratio] Hazard Ratio Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Robertson 1998 -1.427 (0.456) 0.24 [ 0.10, 0.59 ]
0.01 0.1 1 10 100
Favours surgery + RT Favours RT alone
Analysis 4.1. Comparison 4 Positron-emission tomography-computed tomography (PET-CT) versus
planned neck dissection, Outcome 1 Total mortality (HR for overall survival).
Review: Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment
Comparison: 4 Positron-emission tomography-computed tomography (PET-CT) versus planned neck dissection
Outcome: 1 Total mortality (HR for overall survival)
Study or subgroup log [Hazard Ratio] Hazard Ratio Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Mehanna 2017 -0.08 (0.18) 0.92 [ 0.65, 1.31 ]
0.01 0.1 1 10 100
Favours PET-CT Favours planned ND
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A D D I T I O N A L T A B L E S
Table 1. Stage of cancer
Study TNM stage Nodal status
BHNCSG 1998 T2 to T4 Negative neck
Bier 1994 NS Negative or positive neck
D’Cruz 2015 T1 or T2 Negative neck
Fakih 1989 T1 or T2 Negative neck
Guo 2014 T1-T4 Negative or positive neck
Iyer 2015 T3 or T4 Negative or positive neck
Kligerman 1994 T1 or T2 Negative neck
Mehanna 2017 T1-T4 N2 or N3
Rastogi 2018 T1-T3 Negative neck
Robertson 1998 T2-T4 N0 to N2
Vandenbrouck 1980 T1-T3 Negative neck
Yuen 2009 T1 or T2 Negative neck
NS: not stated.
A P P E N D I C E S
Appendix 1. Cochrane Oral Health’s Trials Register search strategy
1 MESH DESCRIPTOR Head and Neck Neoplasms AND INREGISTER
2 MESH DESCRIPTOR Mouth Neoplasms AND INREGISTER
3 MESH DESCRIPTOR Gingival Neoplasms AND INREGISTER
4 MESH DESCRIPTOR Palatal Neoplasms AND INREGISTER
5 MESH DESCRIPTOR Tongue Neoplasms AND INREGISTER
6 ((cancer* or tumour* or tumor* or neoplas* or malignan* or carcinoma* or metatasta*) AND (oral* or intra-oral* or intraoral* or
”intra oral*“ or gingiva* or oropharyn* or mouth* or tongue* or cheek* or gum* or palatal* or palate* or ”head and neck“)) AND
INREGISTER
7 #1 or #2 or #3 or #4 or #5 or #6
8 MESH DESCRIPTOR Surgical Procedures, Operative EXPLODE ALL AND INREGISTER
9 (surgery or surgical or operat*):ti,ab AND INREGISTER
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10 (dissect* NEAR2 neck*):ti,ab AND INREGISTER
11 (excision or excise or resect*):ti,ab AND INREGISTER
12 MESH DESCRIPTOR Lymph Node Excision EXPLODE ALL AND INREGISTER
13 MESH DESCRIPTOR Oral Surgical Procedures AND INREGISTER
14 (lymphadenectom* or glossectom* or maxillectom* or micrographic or mandibulectom* or hemi-mandibulectom* or hemi-
mandibulectom*):ti,ab AND INREGISTER
15 #8 or #9 or #10 or #11 or #12 or #13 or #14
16 #7 and #15
Appendix 2. Cochrane Central Register of Controlled Trials (CENTRAL) search strategy
1. MESH DESCRIPTOR Head and Neck Neoplasms AND CENTRAL:TARGET
2. MESH DESCRIPTOR Mouth Neoplasms AND CENTRAL:TARGET
3. MESH DESCRIPTOR Gingival Neoplasms AND CENTRAL:TARGET
4. MESH DESCRIPTOR Palatal Neoplasms AND CENTRAL:TARGET
5. MESH DESCRIPTOR Tongue Neoplasms AND CENTRAL:TARGET
6. ((cancer* or tumour* or tumor* or neoplas* or malignan* or carcinoma* or metatasta*) AND (oral* or intra-oral* or intraoral*
or ”intra oral*“ or gingiva* or oropharyn* or mouth* or tongue* or cheek* or gum* or palatal* or palate* or ”head and neck“)) AND
CENTRAL:TARGET
7. #1 or #2 or #3 or #4 or #5 or #6
8. MESH DESCRIPTOR Surgical Procedures, Operative EXPLODE ALL AND CENTRAL:TARGET
9. (surgery or surgical or operat*):ti,ab AND CENTRAL:TARGET
10. (dissect* NEAR2 neck*):ti,ab AND CENTRAL:TARGET
11. (excision or excise or resect*):ti,ab AND CENTRAL:TARGET
12. MESH DESCRIPTOR Lymph Node Excision EXPLODE ALL AND CENTRAL:TARGET
13. MESH DESCRIPTOR Oral Surgical Procedures AND CENTRAL:TARGET
14. (lymphadenectom* or glossectom* or maxillectom* or micrographic or mandibulectom* or hemi-mandibulectom* or
hemimandibulectom*):ti,ab AND CENTRAL:TARGET
15. #8 or #9 or #10 or #11 or #12 or #13 or #14
16. #7 and #15
Appendix 3. MEDLINE Ovid search strategy
1 ”Head and neck neoplasms“/
2 ”Mouth neoplasms“/
3 ”Gingival neoplasms“/
4 ”Palatal neoplasms“/
5 ”Tongue neoplasms“/
6 ((cancer$ or tumour$ or tumor$ or neoplas$ or malignan$ or carcinoma$ or
metatasta$) adj5 (oral$ or intra-oral$ or intraoral$ or ”intra oral$“ or gingiva$ or oropharyn$ or mouth$ or tongue$ or cheek$ or
gum$ or palatal$ or palate$ or ”head and neck“)).mp.
7 or/1-6
8 exp Surgical procedures, operative/
9 (surgery or surgical or operat$).mp.
10 (dissect$ adj2 neck$).mp.
11 (excision or excise or resect$).mp.
12 exp Lymph node excision/
13 Oral surgical procedures/
14 (lymphadenectom$ or glossectom$ or maxillectom$ or micrographic or mandibulectom$ or hemi-mandibulectom$ or hemi-
mandibulectom$).ti,ab.
15 or/8-14
16 7 and 15
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This subject search was linked to the Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomised trials in MED-
LINE: sensitivity-maximising version (2008 revision) as referenced in Chapter 6.4.11.1 and detailed in box 6.4.c of The Cochrane
Handbook for Systematic Reviews of Interventions, Version 5.1.0 (updated March 2011) (Lefebvre 2011).
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. drug therapy.fs.
6. randomly.ab.
7. trial.ab.
8. groups.ab.
9. or/1-8
10. exp animals/ not humans.sh.
11. 9 not 10
Appendix 4. Embase Ovid search strategy
1. ”Head and neck tumor“/
2. ”Mouth tumor“/
3. ”Gingiva tumor“/
4. ”Jaw tumor“/
5. ”Tongue tumor“/
6. ((cancer$ or tumour$ or tumor$ or neoplas$ or malignan$ or carcinoma$ or metatasta$) adj5 (oral$ or intra-oral$ or intraoral$ or
”intra oral$“ or gingiva$ or oropharyn$ or mouth$ or tongue$ or cheek$ or gum$ or palatal$ or palate$ or ”head and neck“)).ti,ab.
7. or/1-6
8. exp Oral surgery/
9. (surgery or surgical or operat$).ti,ab.
10. (dissect$ adj2 neck$).ti,ab.
11. (excision or excise or resect$).ti,ab.
12. ”Lymph node dissection“/
13. (lymphadenectom$ or glossectom$ or maxillectom$ or micrographic or mandibulectom$ or hemi-mandibulectom$ or hemi-
mandibulectom$).ti,ab.
14. or/8-13
15. 7 and 14
The above subject search was linked to adapted version of the Cochrane Embase Project filter for identifying RCTs in Embase Ovid
(see www.cochranelibrary.com/help/central-creation-details.html for information):
1. Randomized controlled trial/
2. Controlled clinical study/
3. Random$.ti,ab.
4. randomization/
5. intermethod comparison/
6. placebo.ti,ab.
7. (compare or compared or comparison).ti.
8. ((evaluated or evaluate or evaluating or assessed or assess) and (compare or compared or comparing or comparison)).ab.
9. (open adj label).ti,ab.
10. ((double or single or doubly or singly) adj (blind or blinded or blindly)).ti,ab.
11. double blind procedure/
12. parallel group$1.ti,ab.
13. (crossover or cross over).ti,ab.
14. ((assign$ or match or matched or allocation) adj5 (alternate or group$1 or intervention$1 or patient$1 or subject$1 or partici-
pant$1)).ti,ab.
15. (assigned or allocated).ti,ab.
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16. (controlled adj7 (study or design or trial)).ti,ab.
17. (volunteer or volunteers).ti,ab.
18. trial.ti.
19. or/1-18
20. (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.)
21. 19 not 20
Appendix 5. US National Institutes of Health Ongoing Trials Register (ClinicalTrials.gov) search
strategy
Advanced search: “oral cancer” AND surgery
Limited to interventional studies
Appendix 6. World Health Organization International Clinical Trials Registry Platform search
strategy
Advanced search: oral cancer
WH A T ’ S N E W
Date Event Description
4 December 2018 New citation required and conclusions have changed Conclusions for comparisons already included remain
the same, and have low- to very low-certainty evidence,
but new comparisons have been added
20 December 2017 New search has been performed Search updated and five new studies included. New
comparisons added. New lead author and byline
H I S T O R Y
Protocol first published: Issue 4, 2006
Review first published: Issue 4, 2007
Date Event Description
4 July 2011 New search has been performed Searches updated to 17 February 2011.
4 July 2011 New citation required and conclusions have changed Two new trials added. New comparisons, and conclusions.
Twenty-four previously included trials now moved to other
oral cancer reviews on chemotherapy and radiotherapy
28 April 2009 Amended Minor changes to the data.
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(Continued)
20 June 2008 Amended Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
• VB and HW co-ordinated and managed the review update.
• The trials search strategy was refined with input from VB. (It was designed by Cochrane Oral Health Information Specialist
Anne Littlewood.)
• HW, VB, AMG, DC and MM screened the titles and abstracts.
• HW organised retrieval of papers.
• HW and VB screened retrieved papers against the inclusion criteria.
• VB, HW and AMG extracted data, appraised the risk of bias in the included studies, and assessed the certainty of the body of
evidence for each main comparison and outcome.
• HW and AMG provided a methodological perspective.
• DC, MM and JC provided a clinical perspective.
D E C L A R A T I O N S O F I N T E R E S T
VB: none known.
HW: none known. I am a Co-ordinating Editor of Cochrane Oral Health.
AMG: none known. I am Deputy Co-ordinating Editor of Cochrane Oral Health.
JC: none known. I am a Co-ordinating Editor of Cochrane Oral Health.
DC: none known.
MM: none known.
S O U R C E S O F S U P P O R T
Internal sources
• The School of Dentistry, The University of Manchester, Manchester Academic Health Sciences Centre (MAHSC) and the
NIHR Manchester Biomedical Research Centre, UK.
• The University of Dundee, UK.
• The University of Glasgow, UK.
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External sources
• Cochrane Oral Health Global Alliance, Other.
The production of Cochrane Oral Health reviews has been supported financially by our Global Alliance since 2011 (
oralhealth.cochrane.org/partnerships-alliances). Contributors over the past year have been the American Association of Public Health
Dentistry, USA; AS-Akademie, Germany; the British Association for the Study of Community Dentistry, UK; the British Society of
Paediatric Dentistry, UK; the Canadian Dental Hygienists Association, Canada; the Centre for Dental Education and Research at All
India Institute of Medical Sciences, India; the National Center for Dental Hygiene Research & Practice, USA; New York University
College of Dentistry, USA; and the Swiss Society for Endodontology, Switzerland.
• National Institute for Health Research (NIHR), UK.
This project was supported by the NIHR, via Cochrane Infrastructure funding to Cochrane Oral Health. The views and opinions
expressed herein are those of the review authors and do not necessarily reflect those of the Systematic Reviews Programme, the NIHR,
the NHS or the Department of Health.
• National Institutes of Health, National Institute of Dental & Craniofacial Research, USA.
• Central Manchester & Manchester Children’s University Hospitals NHS Trust, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
This section includes changes that have been made since the previous iterations of the review as well as from protocol.
Types of interventions: the intervention under evaluation must have been surgery. We excluded trials where all participants received
the same surgical regimen and were randomised to other treatments.
Outcomes: local regional control was renamed as locoregional recurrence.
Search methods: the search strategy was updated.
It was considered more appropriate to use random-effect models for any pooling of studies.
The original quality assessment approach was replaced by use of the Cochrane ’Risk of bias’ tool (Higgins 2011).
We updated the data synthesis section. The primary outcome that wasmost reliably and frequently reportedwas total mortality expressed
as a hazard ratio. For dichotomous outcomes, we expressed the estimates of effect of an intervention as RRs with 95% confidence
intervals. Dichotomous data were only used for primary outcomes where hazard ratios were unavailable or could not be calculated.
We performed no subgroup analyses for this update.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Lymph Node Excision [methods; mortality]; Disease-Free Survival; Elective Surgical Procedures [methods; mortality]; Mouth Neo-
plasms [mortality; ∗surgery]; Oropharyngeal Neoplasms [mortality; ∗surgery]; Randomized Controlled Trials as Topic
MeSH check words
Humans
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